

## Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Jeffrey R. Garber,<sup>1,2,\*</sup> Rhoda H. Cobin,<sup>3</sup> Hossein Gharib,<sup>4</sup> James V. Hennessey,<sup>2</sup> Irwin Klein,<sup>5</sup>  
Jeffrey I. Mechanick,<sup>6</sup> Rachel Pessah-Pollack,<sup>6,7</sup> Peter A. Singer,<sup>8</sup> and Kenneth A. Woeber<sup>9</sup>

for the American Association of Clinical Endocrinologists and American Thyroid Association  
Taskforce on Hypothyroidism in Adults

**Background:** Hypothyroidism has multiple etiologies and manifestations. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions. This paper describes evidence-based clinical guidelines for the clinical management of hypothyroidism in ambulatory patients.

**Methods:** The development of these guidelines was commissioned by the American Association of Clinical Endocrinologists (AACE) in association with American Thyroid Association (ATA). AACE and the ATA assembled a task force of expert clinicians who authored this article. The authors examined relevant literature and took an evidence-based medicine approach that incorporated their knowledge and experience to develop a series of specific recommendations and the rationale for these recommendations. The strength of the recommendations and the quality of evidence supporting each was rated according to the approach outlined in the American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Guidelines—2010 update.

**Results:** Topics addressed include the etiology, epidemiology, clinical and laboratory evaluation, management, and consequences of hypothyroidism. Screening, treatment of subclinical hypothyroidism, pregnancy, and areas for future research are also covered.

**Conclusions:** Fifty-two evidence-based recommendations and subrecommendations were developed to aid in the care of patients with hypothyroidism and to share what the authors believe is current, rational, and optimal medical practice for the diagnosis and care of hypothyroidism. A serum thyrotropin is the single best screening test for primary thyroid dysfunction for the vast majority of outpatient clinical situations. The standard treatment is replacement with L-thyroxine. The decision to treat subclinical hypothyroidism when the serum thyrotropin is less than 10 mIU/L should be tailored to the individual patient.

---

By mutual agreement among the authors and the editors of their respective journals, this work is being published jointly in *Thyroid* and *Endocrine Practice*.

\*Jeffrey R. Garber, M.D., is Chair of the American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. All authors after the first author are listed in alphabetical order.

<sup>1</sup>Endocrine Division, Harvard Vanguard Medical Associates, Boston, Massachusetts.

<sup>2</sup>Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

<sup>3</sup>New Jersey Endocrine and Diabetes Associates, Ridgewood, New Jersey.

<sup>4</sup>Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.

<sup>5</sup>The Thyroid Unit, North Shore University Hospital, Manhasset, New York.

<sup>6</sup>Division of Endocrinology, Mount Sinai Hospital, New York, New York.

<sup>7</sup>Division of Endocrinology, ProHealth Care Associates, Lake Success, New York.

<sup>8</sup>Keck School of Medicine, University of Southern California, Los Angeles, California.

<sup>9</sup>UCSF Medical Center at Mount Zion, San Francisco, California.

## INTRODUCTION

THESE UPDATED CLINICAL PRACTICE GUIDELINES (CPGs) (1–3) summarize the recommendations of the authors, acting as a joint American Association of Clinical Endocrinologists (AACE) and American Thyroid Association (ATA) task force for the diagnostic evaluation and treatment strategies for adults with hypothyroidism, as mandated by the Board of Directors of AACE and the ATA.

The ATA develops CPGs to provide guidance and recommendations for particular practice areas concerning thyroid disease, including thyroid cancer. The guidelines are not inclusive of all proper approaches or methods, or exclusive of others. The guidelines do not establish a standard of care, and specific outcomes are not guaranteed. Treatment decisions must be made based on the independent judgment of health care providers and each patient's individual circumstances. A guideline is not intended to take the place of physician judgment in diagnosing and treatment of particular patients (for detailed information regarding ATA guidelines, see the Supplementary Data, available online at [www.liebertpub.com/thy](http://www.liebertpub.com/thy)).

The AACE Medical Guidelines for Clinical Practice are systematically developed statements to assist health care professionals in medical decision making for specific clinical conditions. Most of their content is based on literature reviews. In areas of uncertainty, professional judgment is applied (for detailed information regarding AACE guidelines, see the Supplementary Data).

These guidelines are a document that reflects the current state of the field and are intended to provide a working document for guideline updates since rapid changes in this field are expected in the future. We encourage medical professionals to use this information in conjunction with their best clinical judgment. The presented recommendations may not

be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances.

The guidelines presented here principally address the management of ambulatory patients with biochemically confirmed primary hypothyroidism whose thyroid status has been stable for at least several weeks. They do not deal with myxedema coma. The interested reader is directed to the other sources for this information (4). The organization of the guidelines is presented in Table 1.

Serum thyrotropin (TSH) is the single best screening test for primary thyroid dysfunction for the vast majority of outpatient clinical situations, but it is not sufficient for assessing hospitalized patients or when central hypothyroidism is either present or suspected. The standard treatment is replacement with L-thyroxine which must be tailored to the individual patient. The therapy and diagnosis of subclinical hypothyroidism, which often remains undetected, is discussed. L-triiodothyronine in combination with L-thyroxine for treating hypothyroidism, thyroid hormone for conditions other than hypothyroidism, and nutraceuticals are considered.

## METHODS

This CPG adheres to the 2010 AACE Protocol for Standardized Production of Clinical Practice Guidelines published in *Endocrine Practice* (5). This updated protocol describes a more transparent methodology of rating the clinical evidence and synthesizing recommendation grades. The protocol also stipulates a rigorous multilevel review process.

The process was begun by developing an outline for reviewing the principal clinical aspects of hypothyroidism. Computerized and manual searches of the medical literature and various databases, primarily including Medline®, were based on specific section titles, thereby avoiding inclusion of

TABLE 1. ORGANIZATION OF CLINICAL PRACTICE GUIDELINES FOR HYPOTHYROIDISM IN ADULTS

	Page
<b>Introduction</b>	1201
<b>Methods</b>	1201
Objectives	1204
Guidelines for CPGs	1204
Levels of scientific substantiation and recommendation grades (transparency)	1204
Summary of recommendation grades	1205
<b>Topics Relating to Hypothyroidism</b>	1205
Epidemiology	1205
Primary and secondary etiologies of hypothyroidism	1206
Disorders associated with hypothyroidism	1207
Signs and symptoms of hypothyroidism	1207
Measurement of T <sub>4</sub> and T <sub>3</sub>	1207
Pitfalls encountered when interpreting serum TSH levels	1208
Other diagnostic tests for hypothyroidism	1209
Screening and aggressive case finding for hypothyroidism	1209
When to treat hypothyroidism	1210
L-thyroxine treatment of hypothyroidism	1210
Therapeutic endpoints in the treatment of hypothyroidism	1213
When to consult an endocrinologist	1214
Concurrent conditions of special significance in hypothyroid patients	1214
Hypothyroidism during pregnancy	1214
Diabetes mellitus	1215
Infertility	1215

(continued)

TABLE 1. (CONTINUED)

	<i>Page</i>
Obesity	1215
Patients with normal thyroid tests	1215
Depression	1215
Nonthyroidal illness	1215
<i>Dietary supplements and nutraceuticals in the treatment of hypothyroidism</i>	1216
<i>Overlap of symptoms in euthyroid and hypothyroid patients</i>	1216
<i>Excess iodine intake and hypothyroidism</i>	1216
<i>Desiccated thyroid</i>	1216
<i>3,5,3'-Triiodothyroacetic acid</i>	1217
<i>Thyroid-enhancing preparations</i>	1217
<i>Thyromimetic preparations</i>	1217
<i>Selenium</i>	1217
<b>Questions and Guideline Recommendations</b>	1217
Q1 <i>When should anti-thyroid antibodies be measured?</i>	1217
R1 TPOAb measurements and subclinical hypothyroidism	1217
R2 TPOAb measurements and nodular thyroid disease	1217
R3 TPOAb measurements and recurrent miscarriage	1217
R4 TSHRAb measurements in women with Graves' disease who have had thyroidectomy or RAI treatment before pregnancy	1217
Q2 <i>What is the role of clinical scoring systems in the diagnosis of patients with hypothyroidism?</i>	1218
R5 Do not use clinical scoring systems to diagnose hypothyroidism	1218
Q3 <i>What is the role of diagnostic tests apart from serum thyroid hormone levels and TSH in the evaluation of patients with hypothyroidism?</i>	1218
R6 Do not use indirect tests to diagnose hypothyroidism	1218
Q4 <i>What are the preferred thyroid hormone measurements in addition to TSH in the assessment of patients with hypothyroidism?</i>	1218
R7 When to use free T <sub>4</sub> vs. total T <sub>4</sub>	1218
R8 Using free T <sub>4</sub> to monitor L-thyroxine treatment	1218
R9 Estimating serum free T <sub>4</sub> in pregnancy	1218
R10 Prohibition against using T <sub>3</sub> to diagnose hypothyroidism	1218
R11 Measuring TSH in hospitalized patients	1218
R12 Serum T <sub>4</sub> vs. TSH for management of central hypothyroidism	1218
Q5 <i>When should TSH levels be measured in patients being treated for hypothyroidism?</i>	1218
R13 When to measure TSH in patients taking L-thyroxine for hypothyroidism	1218
Q6 <i>What should be considered the upper limit of the normal range of TSH values?</i>	1218
R14.1 Reference ranges for TSH, age, and lab variability	1218
R14.2 Reference ranges for TSH in pregnant women	1218
Q7 <i>Which patients with TSH levels above a given laboratory's reference range should be considered for treatment with L-thyroxine?</i>	1219
R15 Treating patients with TSH above 10 mIU/L	1219
R16 Treating if TSH is elevated but below 10 mIU/L	1219
Q8 <i>In patients with hypothyroidism being treated with L-thyroxine what should the target TSH ranges be?</i>	1219
R17 Target TSH when treating hypothyroidism	1219
Q9 <i>In patients with hypothyroidism being treated with L-thyroxine who are pregnant, what should the target TSH ranges be?</i>	1219
R18 Target TSH when treating hypothyroid pregnant women	1219
Q10 <i>Which patients with normal serum TSH levels should be considered for treatment with L-thyroxine?</i>	1219
R19.1 L-thyroxine treatment in pregnant women with "normal" TSH	1219
R19.2 L-thyroxine treatment in women of child-bearing age or pregnant with "normal" TSH and have positive TPOAb or history of miscarriage or hypothyroidism	1219
R19.3 L-thyroxine treatment in pregnant women or those planning pregnancy with TPOAb and serum TSH is >2.5 mIU/L	1219
R19.4 Monitoring of pregnant women with TPOAb or a "normal" TSH but >2.5 mIU/L who are not taking L-thyroxine	1219
Q11 <i>Who, among patients who are pregnant, or planning pregnancy, or with other characteristics, should be screened for hypothyroidism?</i>	1220
R20.1.1 Universal screening of women planning pregnancy included assisted reproduction	1220
R20.1.2 Aggressive case finding for hypothyroidism for women planning pregnancy	1220
R20.2 Age and screening for hypothyroidism	1220

(continued)

TABLE 1. (CONTINUED)

	Page	
R21	Aggressive case finding for hypothyroidism—whom to target	1220
Q12	<i>How should patients with hypothyroidism be treated and monitored?</i>	1220
R22.1	Form of thyroid hormone for treatment of hypothyroidism	1220
R22.2	L-thyroxine and L-triiodothyronine combinations to treat hypothyroidism	1220
R22.3	Prohibition against using L-thyroxine and L-triiodothyronine combinations to treat pregnant women or those planning pregnancy	1220
R22.4	Prohibition against using desiccated thyroid hormone to treat hypothyroidism	1220
R22.5	Prohibition against using TRIAC (tiratricol) to treat hypothyroidism	1220
R22.6	Resuming L-thyroxine treatment for hypothyroidism in patients without cardiac events	1220
R22.7.1	L-thyroxine treatment for overt hypothyroidism in young healthy adults	1220
R22.7.2	L-thyroxine treatment for overt hypothyroidism in patients older than 50 to 60 years	1220
R22.8	L-thyroxine treatment for subclinical hypothyroidism compared to overt hypothyroidism	1220
R22.9	Order of L-thyroxine treatment and glucocorticoids in patients with adrenal insufficiency and hypothyroidism	1221
R23	L-thyroxine treatment for hypothyroidism—time to take, method of taking, and storage	1221
R24	Free T <sub>4</sub> as the target measurement when treating central hypothyroidism	1221
R25.1	Testing and treating women with hypothyroidism as soon as they become pregnant	1221
R25.2	Goal TSH in pregnant women with hypothyroidism	1221
R25.3	Monitoring pregnant women with hypothyroidism	1221
R26	Monitoring hypothyroid patients who start drugs affecting T <sub>4</sub> bioavailability or metabolism	1221
R27	Prohibition against targeting specific TSH values in hypothyroid patients who are not pregnant	1221
Q13	<i>When should endocrinologists be involved in the care of patients with hypothyroidism?</i>	1221
R28	Type of hypothyroid patient who should be seen in consultation with an endocrinologist	1221
Q14	<i>Which patients should not be treated with thyroid hormone?</i>	1221
R29	Need for biochemical confirmation of the diagnosis before chronic treatment of hypothyroidism	1221
R30	Prohibition against using thyroid hormone to treat obesity	1221
R31	Thyroid hormone treatment and depression	1222
Q15	<i>What is the role of iodine supplementation, dietary supplements, and nutraceuticals in the treatment of hypothyroidism?</i>	1222
R32.1	Prohibition against using iodine supplementation to treat hypothyroidism in iodine-sufficient areas	1222
R32.2	Inappropriate method for iodine supplementation in pregnant women	1222
R33	Prohibition against using selenium as treatment or preventive measure for hypothyroidism	1222
R34	Recommendation regarding dietary supplements, nutraceuticals, and products marked as “thyroid support” for hypothyroidism	1222
<b>Areas for Future Research</b>		1222
	<i>Cardiac benefit from treating subclinical hypothyroidism</i>	1222
	<i>Cognitive benefit from treating subclinical hypothyroidism</i>	1223
	<i>L-thyroxine/L-triiodothyronine combination therapy</i>	1223
	<i>L-triiodothyronine monotherapy</i>	1223
	<i>Thyroid hormone analogues</i>	1223
	<i>Screening for hypothyroidism in pregnancy</i>	1223
	<i>Agents and conditions having an impact on L-thyroxine therapy and interpretation of thyroid tests</i>	1223
<b>Author Disclosure Statement</b>		1224
<b>Acknowledgments</b>		1224
<b>References including authors' evidence level (EL) rankings</b>		1224
<b>Supplementary Data</b>		Online at <a href="http://www.liebertpub.com/thy">www.liebertpub.com/thy</a>
	1. Supplementary information regarding ATA and AACE guidelines	
	2. Complete list of guideline recommendations	

*Note:* When referring to therapy and therapeutic preparations in the recommendations and elsewhere, L-thyroxine and L-triiodothyronine are generally used instead of their respective hormonal equivalents, T<sub>4</sub> and T<sub>3</sub>.

AACE, American Association of Clinical Endocrinologists; ATA, American Thyroid Association; CPG, Clinical Practice Guideline; RAI, radioactive iodine; T<sub>3</sub>, triiodothyronine; T<sub>4</sub>, thyroxine; TPOAb, anti-thyroid peroxidase antibodies; TRIAC, 3,5,3'-triiodothyroacetic acid; TSH, thyrotropin; TSHRAb, TSH receptor antibodies.

unnecessary detail and exclusion of important studies. Compilation of the bibliography was a continual and dynamic process. Once the principal clinical aspects of hypothyroidism were defined, questions were formulated with the intent to then develop recommendations that addressed these questions. The grading of recommendations was based on consensus among the authors.

The final document was approved by the American Association of Clinical Endocrinologists (AACE) and American Thyroid Association (ATA), and was officially endorsed by the American Association of Diabetes Educators (AADE), American Association of Endocrine Surgeons (AAES), American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS), American College of Endocrinology (ACE), Italian Association of Clinical Endocrinologists (AME), American Society for Metabolic & Bariatric Surgery (ASMBS), The Endocrine Society of Australia (ESA), International Association of Endocrine Surgeons (IAES), Latin American Thyroid Society (LATS), and Ukrainian Association of Endocrine Surgeons (UAES).

### Objectives

The purpose of these guidelines is to present an updated evidence-based framework for the diagnosis, treatment, and follow-up of patients with hypothyroidism.

### Guidelines for CPGs

Current guidelines for CPGs in clinical medicine emphasize an evidence-based approach rather than simply expert opin-

ion (6). Even though a purely evidence-based approach is not applicable to all actual clinical scenarios, we have incorporated this into these CPGs to provide objectivity.

### Levels of scientific substantiation and recommendation grades (transparency)

All clinical data that are incorporated in these CPGs have been evaluated in terms of levels of scientific substantiation. The detailed methodology for assigning evidence levels (ELs) to the references used in these CPGs has been reported by Mechanick *et al.* (7), from which Table 2 is taken. The authors' EL ratings of the references are included in the References section. The four-step approach that the authors used to grade recommendations is summarized in Tables 3, 4, 5, and 6 of the 2010 Standardized Production of Clinical Practice Guidelines (5), from which Table 3 is taken. By explicitly providing numerical and semantic descriptors of the clinical evidence as well as relevant subjective factors and study flaws, the updated protocol has greater transparency than the 2008 AACE protocol described by Mechanick *et al.* (7).

In these guidelines, the grading system used for the recommendations does not reflect the instruction of the recommendation, but the strength of the recommendation. For example in some grading systems "should not" implies that there is substantial evidence to support a recommendation. However the grading method employed in this guideline

TABLE 2. LEVELS OF SCIENTIFIC SUBSTANTIATION IN EVIDENCE-BASED MEDICINE

Level	Description	Comments
1	Prospective, randomized, controlled trials—large	Data are derived from a substantial number of trials with adequate statistical power involving a substantial number of outcome data subjects. Large meta-analyses using raw or pooled data or incorporating quality ratings Well-controlled trial at one or more centers Consistent pattern of findings in the population for which the recommendation is made (generalizable data). Compelling nonexperimental, clinically obvious, evidence (e.g., thyroid hormone treatment for myxedema coma), "all-or-none" indication
2	Prospective controlled trials with or without randomization—limited body of outcome data	Limited number of trials, small population sites in trials Well-conducted single-arm prospective cohort study Limited but well-conducted meta-analyses Inconsistent findings or results not representative for the target population Well-conducted case-controlled study
3	Other experimental outcome data and nonexperimental data	Nonrandomized, controlled trials Uncontrolled or poorly controlled trials Any randomized clinical trial with one or more major or three or more minor methodological flaws Retrospective or observational data Case reports or case series Conflicting data with weight of evidence unable to support a final recommendation
4	Expert opinion	Inadequate data for inclusion in level 1, 2, or 3; necessitates an expert panel's synthesis of the literature and a consensus Experience based Theory driven

Levels 1, 2, and 3 represent a given level of scientific substantiation or proof. Level 4 or Grade D represents unproven claims. It is the "best evidence" based on the individual ratings of clinical reports that contributes to a final grade recommendation.

Source: Mechanick *et al.*, 2008 (7).

TABLE 3. GRADE-RECOMMENDATION PROTOCOL

*2010 AACE Protocol for Production of Clinical Practice Guidelines—Step III: Grading of recommendations; How different evidence levels can be mapped to the same recommendation grade*

Best evidence level	Subjective factor impact	Two-thirds consensus	Mapping <sup>a</sup>	Recommendation grade
1	None	Yes	Direct	A
2	Positive	Yes	Adjust up	A
2	None	Yes	Direct	B
1	Negative	Yes	Adjust down	B
3	Positive	Yes	Adjust up	B
3	None	Yes	Direct	C
2	Negative	Yes	Adjust down	C
4	Positive	Yes	Adjust up	C
4	None	Yes	Direct	D
3	Negative	Yes	Adjust down	D
1,2,3,4	N/A	No	Adjust down	D

Adopted by the AACE and the ATA for the Hypothyroidism CPG.

<sup>a</sup>Starting with the left column, best evidence levels (BELs), subjective factors, and consensus map to recommendation grades in the right column. When subjective factors have little or no impact (“none”), then the BEL is directly mapped to recommendation grades. When subjective factors have a strong impact, then recommendation grades may be adjusted up (“positive” impact) or down (“negative” impact). If a two-thirds consensus cannot be reached, then the recommendation grade is D.

Source: Mechanick *et al.*, 2010 (5).

N/A, not applicable (regardless of the presence or absence of strong subjective factors, the absence of a two-thirds consensus mandates a recommendation grade D).

enables authors to use this language even when the best evidence level available is “expert opinion.” Although different grading systems were employed, an effort was made to make these recommendations consistent with related portions of “Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists” (8,9), as well as the “Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum” (10).

The shortcomings of this evidence-based methodology in these CPGs are that many recommendations are based on weak scientific data (Level 3) or consensus opinion (Level 4), rather than strong scientific data (Levels 1 and 2). There are also the problems of (i) subjectivity on the part of the authors when weighing positive and negative, or epidemiologic versus experimental, data in order to arrive at an evidence-

based recommendation grade or consensus opinion, (ii) subjectivity on the part of the authors when weighing subjective attributes, such as cost effectiveness and risk-to-benefit ratios, in order to arrive at an evidence-based recommendation grade or consensus opinion, (iii) potentially incomplete review of the literature by the authors despite extensive diligence, and (iv) bias in the available publications, which originate predominantly from experienced clinicians and large academic medical centers and may, therefore, not reflect the experience at large. The authors, through an *a priori* methodology and multiple levels of review, have tried to address these shortcomings by discussions with three experts (see **Acknowledgments**).

### Summary of recommendation grades

The recommendations are evidence-based (Grades A, B, and C) or based on expert opinion because of a lack of conclusive clinical evidence (Grade D). The “best evidence” rating level (BEL), which corresponds to the best conclusive evidence found, accompanies the recommendation grade. Details regarding the mapping of clinical evidence ratings to these recommendation grades have already been provided [see *Levels of scientific substantiation and recommendation grades (transparency)*]. In this CPG, a substantial number of recommendations are upgraded or downgraded because the conclusions may not apply in other situations (non-generalizability). For example, what applies to an elderly population with established cardiac disease may not apply to a younger population without cardiac risk factors. Whenever expert opinions resulted in upgrading or downgrading a recommendation, it is explicitly stated after the recommendation.

## TOPICS RELATING TO HYPOTHYROIDISM

### Epidemiology

Hypothyroidism may be either subclinical or overt. Subclinical hypothyroidism is characterized by a serum TSH above the upper reference limit in combination with a normal free thyroxine (T<sub>4</sub>). This designation is only applicable when thyroid function has been stable for weeks or more, the hypothalamic-pituitary-thyroid axis is normal, and there is no recent or ongoing severe illness. An elevated TSH, usually above 10 mIU/L, in combination with a subnormal free T<sub>4</sub> characterizes overt hypothyroidism.

The results of four studies are summarized in Table 4. The National Health and Nutrition Examination Survey (NHANES III) studied an unselected U.S. population over age 12 between 1988 and 1994, using the upper limit of normal for

TABLE 4. PREVALENCE OF HYPOTHYROIDISM

Study	Subclinical	Overt	TSH	Comment
NHANES III	4.3%	0.3%	4.5	
Colorado Thyroid Disease Prevalence	8.5%	0.4%	5.0	Not on thyroid hormone
Framingham			10.0	Over age 60 years: 5.9% women; 2.3% men; 39% of whom had subnormal T <sub>4</sub>
British Whickham			10.0	9.3% women; 1.2% men

Sources: Hollowell *et al.*, 2002 (11); Canaris *et al.*, 2000 (12); Sawin *et al.*, 1985 (13); Vanderpump *et al.*, 1995 (14); Vanderpump and Tunbridge, 2002 (15).

NHANES, National Health and Nutrition Examination Survey.

TSH as 4.5 mIU/mL (11). The prevalence of subclinical disease was 4.3% and of overt disease was 0.3%. The Colorado thyroid disease prevalence survey, in which self-selected individuals attending a health fair were tested and an upper normal TSH value of 5.0 mIU/L was used, reported a prevalence of 8.5% and 0.4% for subclinical and overt disease, respectively, in people not taking thyroid hormone (12). In the Framingham study, 5.9% of women and 2.3% of men over the age of 60 years had TSH values over 10 mIU/L, 39% of whom had subnormal T<sub>4</sub> levels (13). In the British Whickham survey 9.3% of women and 1.2% of men had serum TSH values over 10 mIU/L (14,15). The incidence of hypothyroidism in women was 3.5 per 1000 survivors per year and in men it was 0.6 per 1000 survivors per year. The risk of developing hypothyroidism in women with positive antibodies and elevated TSH was 4% per year versus 2%–3% per year in those with either alone (14,15). In men the relative risk rose even more in each category, but the rates remained well below those of women.

### **Primary and secondary etiologies of hypothyroidism**

Environmental iodine deficiency is the most common cause of hypothyroidism on a worldwide basis (16). In areas of iodine sufficiency, such as the United States, the most common cause of hypothyroidism is chronic autoimmune thyroiditis (Hashimoto's thyroiditis). Autoimmune thyroid diseases (AITDs) have been estimated to be 5–10 times more common in women than in men. The ratio varies from series to series and is dependent on the definition of disease, whether it is clinically evident or not. In the Whickham survey (14), for example, 5% of women and 1% of men had both positive antibody tests and a serum TSH value >6. This form of AITD (i.e., Hashimoto's thyroiditis, chronic autoimmune thyroiditis) increases in frequency with age (11), and is more common in people with other autoimmune diseases and their families (17–25). Goiter may or may not be present.

AITDs are characterized pathologically by infiltration of the thyroid with sensitized T lymphocytes and serologically by circulating thyroid autoantibodies. Autoimmunity to the thyroid gland appears to be an inherited defect in immune surveillance, leading to abnormal regulation of immune responsiveness or alteration of presenting antigen in the thyroid (26,27).

One of the keys to diagnosing AITDs is determining the presence of elevated anti-thyroid antibody titers which include anti-thyroglobulin antibodies (TgAb), anti-microsomal/thyroid peroxidase antibodies (TPOAb), and TSH receptor antibodies (TSHRAb). Many patients with chronic autoimmune thyroiditis are biochemically euthyroid. However, approximately 75% have elevated anti-thyroid antibody titers. Once present, these antibodies generally persist, with spontaneous disappearance occurring infrequently. Among the disease-free population in the NHANES survey, tests for TgAb were positive in 10.4% and TPOAb in 11.3%. These antibodies were more common in women than men and increased with age. Only positive TPOAb tests were significantly associated with hypothyroidism (11). The presence of elevated TPOAb titers in patients with subclinical hypothyroidism helps to predict progression to overt hypothyroidism—4.3% per year with TPOAb vs. 2.6% per year

without elevated TPOAb titers (14,28). The higher risk of developing overt hypothyroidism in TPOAb-positive patients is the reason that several professional societies and many clinical endocrinologists endorse measurement of TPOAbs in those with subclinical hypothyroidism.

In patients with a diffuse, firm goiter, TPOAb should be measured to identify autoimmune thyroiditis. Since non-immunologically mediated multinodular goiter is rarely associated with destruction of functioning tissue and progression to hypothyroidism (29), it is important to identify those patients with the nodular variant of autoimmune thyroiditis in whom these risks are significant. In some cases, particularly in those with thyroid nodules, fine-needle aspiration (FNA) biopsy helps confirm the diagnosis and to exclude malignancy. Also, in patients with documented hypothyroidism, measurement of TPOAb identifies the cause.

In the presence of other autoimmune disease such as type 1 diabetes (20,21) or Addison's disease (17,18), chromosomal disorders such as Down's (30) or Turner's syndrome (31), and therapy with drugs such as lithium (32–34), interferon alpha (35,36), and amiodarone (37) or excess iodine ingestion (e.g., kelp) (38–40), TPOAb measurement may provide prognostic information on the risk of developing hypothyroidism.

TSHRAb may act as a TSH agonist or antagonist (41). Thyroid stimulating immunoglobulin (TSI) and/or thyrotropin binding inhibitory immunoglobulin (TBII) levels, employing sensitive assays, should be measured in euthyroid or L-thyroxine-treated hypothyroid pregnant women with a history of Graves' disease because they are predictors of fetal and neonatal thyrotoxicosis (42). Since the risk for thyrotoxicosis correlates with the magnitude of elevation of TSI, and since TSI levels tend to fall during the second trimester, TSI measurements are most informative when done in the early third trimester. The argument for measurement earlier in pregnancy is also based, in part, on determining whether establishing a surveillance program for ongoing fetal and subsequent neonatal thyroid dysfunction is necessary (43).

Hypothyroidism may occur as a result of radioiodine or surgical treatment for hyperthyroidism, thyroid cancer, or benign nodular thyroid disease and after external beam radiation for non-thyroid-related head and neck malignancies, including lymphoma. A relatively new pharmacologic cause of iatrogenic hypothyroidism is the tyrosine kinase inhibitors, most notably sunitinib (44,45), which may induce hypothyroidism through reduction of glandular vascularity and induction of type 3 deiodinase activity.

Central hypothyroidism occurs when there is insufficient production of bioactive TSH (46,47) due to pituitary or hypothalamic tumors (including craniopharyngiomas), inflammatory (lymphocytic or granulomatous hypophysitis) or infiltrative diseases, hemorrhagic necrosis (Sheehan's syndrome), or surgical and radiation treatment for pituitary or hypothalamic disease. In central hypothyroidism, serum TSH may be mildly elevated, but assessment of serum free T<sub>4</sub> is usually low, differentiating it from subclinical primary hypothyroidism.

Consumptive hypothyroidism is a rare condition that may occur in patients with hemangiomas and other tumors in which type 3 iodothyronine deiodinase is expressed, resulting in accelerated degradation of T<sub>4</sub> and triiodothyronine (T<sub>3</sub>) (48,49).

### Disorders associated with hypothyroidism

The most common form of thyroid failure has an autoimmune etiology. Not surprisingly, there is also an increased frequency of other autoimmune disorders in this population such as type 1 diabetes, pernicious anemia, primary adrenal failure (Addison's disease), myasthenia gravis, celiac disease, rheumatoid arthritis, systemic lupus erythematosus (17–25), and rarely thyroid lymphoma (50).

Distinct genetic syndromes with multiple autoimmune endocrinopathies have been described, with some overlapping clinical features. The presence of two of the three major characteristics is required to diagnose the syndrome of multiple autoimmune endocrinopathies (MAEs). The defining major characteristics for type 1 MAE and type 2 MAE are as follows:

- Type 1 MAE: Hypoparathyroidism, Addison's disease, and mucocutaneous candidiasis caused by mutations in the autoimmune regulator gene (AIRE), resulting in defective AIRE protein (51). Autoimmune thyroiditis is present in about 10%–15% (52).
- Type 2 MAE: Addison's disease, autoimmune thyroiditis, and type 1 diabetes known as Schmidt's syndrome (53).

When adrenal insufficiency is present, the diagnosis of subclinical hypothyroidism should be deferred until after glucocorticoid therapy has been instituted because TSH levels may be elevated in the presence of untreated adrenal insufficiency and may normalize with glucocorticoid therapy (54,55) (see *L-thyroxine treatment of hypothyroidism*).

### Signs and symptoms of hypothyroidism

The well-known signs and symptoms of hypothyroidism tend to be more subtle than those of hyperthyroidism. Dry skin, cold sensitivity, fatigue, muscle cramps, voice changes, and constipation are among the most common. Less commonly appreciated and typically associated with severe hypothyroidism are carpal tunnel syndrome, sleep apnea, pituitary hyperplasia that can occur with or without hyperprolactinemia and galactorrhea, and hyponatremia that can occur within several weeks of the onset of profound hypothyroidism. Although, for example, in the case of some symptoms such as voice changes subjective (12,56) and objective (57) measures differ. Several rating scales (56,58,59) have been used to assess the presence and, in some cases, the severity of hypothyroidism, but have low sensitivity and specificity. While the exercise of calculating clinical scores has been largely superseded by sensitive thyroid function tests, it is useful to have objective clinical measures to gauge the severity of hypothyroidism. Early as well as recent studies strongly correlate the degree of hypothyroidism with ankle reflex relaxation time, a measure rarely used in current clinical practice today (60).

Normalization of a variety of clinical and metabolic end points including resting heart rate, serum cholesterol, anxiety level, sleep pattern, and menstrual cycle abnormalities including menometrorrhagia are further confirmatory findings that patients have been restored to a euthyroid state (61–65). Normalization of elevated serum creatine kinase or other muscle (66) or hepatic enzymes following treatment of hypothyroidism (67) are additional, less well-appreciated and also nonspecific therapeutic endpoints.

### Measurement of T<sub>4</sub> and T<sub>3</sub>

T<sub>4</sub> is bound to specific binding proteins in serum. These are T<sub>4</sub>-binding globulin (TBG) and, to a lesser extent, transthyretin or T<sub>4</sub>-binding prealbumin and albumin. Since approximately 99.97% of T<sub>4</sub> is protein-bound, levels of serum total T<sub>4</sub> will be affected by factors that alter binding independent of thyroid disease (Table 5) (68,69). Accordingly, methods for assessing (including estimating and measuring) serum free T<sub>4</sub>, which is the metabolically available moiety (70), have been developed, and assessment of serum free T<sub>4</sub> has now largely replaced measurement of serum total T<sub>4</sub> as a measure of thyroid status. These methods include the serum free T<sub>4</sub> index, which is derived as the product of total T<sub>4</sub> and a thyroid hormone binding ratio, and the direct immunoassay of free T<sub>4</sub> after ultrafiltration or equilibrium dialysis of serum or after addition of anti-T<sub>4</sub> antibody to serum (71).

A subnormal assessment of serum free T<sub>4</sub> serves to establish a diagnosis of hypothyroidism, whether primary, in which serum TSH is elevated, or central, in which serum TSH is normal or low (46,47). An assessment of serum free T<sub>4</sub> (Table 6) is the primary test for detecting hypothyroidism in antithyroid drug-treated or surgical or radioiodine-ablated patients with previous hyperthyroidism in whom serum TSH may remain low for many weeks to months.

In monitoring patients with hypothyroidism on L-thyroxine replacement, blood for assessment of serum free T<sub>4</sub> should be collected before dosing because the level will be transiently increased by up to 20% after L-thyroxine administration (72). In one small study of athyreotic patients, serum total T<sub>4</sub> levels increased above baseline by 1 hour and peaked at 2.5 hours, while serum free T<sub>4</sub> levels peaked at 3.5 hours and remained higher than baseline for 9 hours (72).

In pregnancy, measurement of serum total T<sub>4</sub> is recommended over direct immunoassay of serum free T<sub>4</sub>. Because of alterations in serum proteins in pregnancy, direct immunoassay of free T<sub>4</sub> may yield lower values based on reference ranges established with normal nonpregnant sera. Moreover, many patients will have values below the nonpregnant reference range in the third trimester, including

TABLE 5. FACTORS THAT ALTER THYROXINE AND TRIIODOTHYRONINE BINDING IN SERUM

Increased TBG	Decreased TBG	Binding inhibitors
Inherited	Inherited	Salicylates
Pregnancy	Androgens	Furosemide
Neonatal state	Anabolic steroids	Free fatty acids
Estrogens	Glucocorticoids	Phenytoin
Hepatitis	Severe illness	Carbamazepine
Porphyria	Hepatic failure	NSAIDs (variable, transient)
Heroin	Nephrosis	Heparin
Methadone	Nicotinic acid	
Mitotane	L-Asparaginase	
5-Fluorouracil		
SERMS (e.g., tamoxifen, raloxifene)		
Perphenazine		

TBG, T<sub>4</sub>-binding globulin; SERMS, selective estrogen receptor modulators; NSAIDs, nonsteroidal anti-inflammatory drugs.



TABLE 6. ASSESSMENT OF FREE THYROXINE

Test	Method	Comments
Free T <sub>4</sub> index or free T <sub>4</sub> estimate	Product of total T <sub>4</sub> and thyroid hormone binding ratio or T <sub>3</sub> -resin uptake	Normal values in pregnancy and with alterations in TBG binding;
Direct immunoassay of free T <sub>4</sub>	With physical separation using equilibrium dialysis or ultrafiltration	Reduced values in pregnancy compared to nonpregnant reference ranges; normal values with alterations in TBG binding
Direct immunoassay of free T <sub>4</sub>	Without physical separation using anti-T <sub>4</sub> antibody	Reduced values in pregnancy compared to nonpregnant reference ranges; normal values with alterations in TBG binding

values obtained with equilibrium dialysis (73). Finally, method-specific and trimester-specific reference ranges for direct immunoassay of free T<sub>4</sub> have not been generally established. By contrast, total T<sub>4</sub> increases during the first trimester and the reference range is ~1.5-fold that of the nonpregnant range throughout pregnancy (73,74).

As is the case with T<sub>4</sub>, T<sub>3</sub> is also bound to serum proteins, principally TBG, but to a lesser extent than T<sub>4</sub>, ~99.7%. Methods for assessing free T<sub>3</sub> concentration by direct immunoassay have been developed and are in current use (71). However, serum T<sub>3</sub> measurement, whether total or free, has limited utility in hypothyroidism because levels are often normal due to hyperstimulation of the remaining functioning thyroid tissue by elevated TSH and to up-regulation of type 2 iodothyronine deiodinase (75). Moreover, levels of T<sub>3</sub> are low in the absence of thyroid disease in patients with severe illness because of reduced peripheral conversion of T<sub>4</sub> to T<sub>3</sub> and increased inactivation of thyroid hormone (76,77).

#### **Pitfalls encountered when interpreting serum TSH levels**

Measurement of serum TSH is the primary screening test for thyroid dysfunction, for evaluation of thyroid hormone replacement in patients with primary hypothyroidism, and for assessment of suppressive therapy in patients with follicular cell-derived thyroid cancer. TSH levels vary diurnally by up to approximately 50% of mean values (78), with more recent reports indicating up to 40% variation on specimens performed serially during the same time of day (79). Values tend to be lowest in the late afternoon and highest around the hour of sleep. In light of this, variations of serum TSH values within the normal range of up to 40%–50% do not necessarily reflect a change in thyroid status.

TSH secretion is exquisitely sensitive to both minor increases and decreases in serum free T<sub>4</sub>, and abnormal TSH levels occur during developing hypothyroidism and hyperthyroidism before free T<sub>4</sub> abnormalities are detectable (80). According to NHANES III (11), a disease-free population, which excludes those who self-reported thyroid disease or goiter or who were taking thyroid medications, the upper normal of serum TSH levels is 4.5 mIU/L. A “reference population” taken from the disease-free population composed of those who were not pregnant, did not have laboratory evidence of hyperthyroidism or hypothyroidism, did not have detectable TgAb or TPOAb, and were not taking estrogens, androgens, or lithium had an upper normal TSH value of 4.12 mIU/L. This was further supported by the Hanford Thyroid Disease Study, which analyzed a cohort without

evidence of thyroid disease, were seronegative for thyroid autoantibodies, were not on thyroid medications, and had normal thyroid ultrasound examinations (which did not disclose nodularity or evidence of thyroiditis) (81). This upper normal value, however, may not apply to iodine insufficient regions even after becoming iodine sufficient for 20 years (82,83).

More recently (84) the NHANES III reference population was further analyzed and normal ranges based on age, U.S. Office of Management of Budget “Race and Ethnicity” categories, and sex were determined. These indicated the 97.5th percentile TSH values as low as 3.24 for African Americans between the ages of 30 and 39 years and as high as 7.84 for Mexican Americans ≥80 years of age. For every 10-year age increase after 30–39 years, the 97.5th percentile of serum TSH increases by 0.3 mIU/L. Body weight, anti-thyroid antibody status, and urinary iodine had no significant impact on these ranges.

The National Academy of Clinical Biochemists, however, indicated that 95% of individuals without evidence of thyroid disease have TSH concentrations below 2.5 mIU/L (85), and it has been suggested that the upper limit of the TSH reference range be lowered to 2.5 mIU/L (86). While many patients with TSH concentrations in this range do not develop hypothyroidism, those patients with AITD are much more likely to develop hypothyroidism, either subclinical or overt (87) (see *Therapeutic endpoints in the treatment of hypothyroidism* for further discussion).

In individuals without serologic evidence of AITD, TSH values above 3.0 mIU/L occur with increasing frequency with age, with elderly (>80 years of age) individuals having a 23.9% prevalence of TSH values between 2.5 and 4.5 mIU/L, and a 12% prevalence of TSH concentrations above 4.5 mIU/L (88). Thus, very mild TSH elevations in older individuals may not reflect subclinical thyroid dysfunction, but rather be a normal manifestation of aging. The caveat is that while the normal TSH reference range—particularly for some subpopulations—may need to be narrowed (85,86), the normal reference range may widen with increasing age (84). Thus, not all patients who have mild TSH elevations are hypothyroid and therefore would not require thyroid hormone therapy.

There are other pitfalls in the interpretation of the serum TSH because abnormal levels are observed in various non-thyroidal states. Serum TSH may be suppressed in hospitalized patients with acute illness, and levels below 0.1 mIU/L in combination with subnormal free T<sub>4</sub> estimates may be seen in critically ill patients, especially in those receiving dopamine infusions (89) or pharmacologic doses of glucocorticoids (90). In addition, TSH levels may increase to levels above normal,

but generally below 20 mIU/L during the recovery phase from nonthyroidal illness (91). Thus, there are limitations to TSH measurements in hospitalized patients and, therefore, they should be only performed if there is an index of suspicion for thyroid dysfunction (76).

Serum TSH typically falls, but infrequently to below 0.1 mIU/L, during the first trimester of pregnancy due to the thyroid stimulatory effects of human chorionic gonadotropin and returns to normal in the second trimester (10) (see Table 7).

TSH secretion may be inhibited by administration of subcutaneous octreotide, which does not cause persistent central hypothyroidism (92), and by oral bexarotene, which almost always does (93). In addition, patients with anorexia nervosa may have low TSH levels in combination with low levels of free T<sub>4</sub> (94), mimicking what may be seen in critically ill patients and in patients with central hypothyroidism due to pituitary and hypothalamic disorders.

Patients with nonfunctioning pituitary adenomas, with central hypothyroidism, may have mildly elevated serum TSH levels, generally not above 6 or 7 mIU/L, due to secretion of bioinactive isoforms of TSH (47). TSH levels may also be elevated in association with elevated serum thyroid hormone levels in patients with resistance to thyroid hormone (95). Heterophilic or interfering antibodies, including human antianimal (most commonly mouse) antibodies, rheumatoid factor, and autoimmune anti-TSH antibodies may cause falsely elevated serum TSH values (96). Lastly, adrenal insufficiency, as previously noted in *Disorders associated with hypothyroidism*, may be associated with TSH elevations that are reversed with glucocorticoid replacement (54,55).

#### Other diagnostic tests for hypothyroidism

Prior to the advent of routine validated chemical measurements of serum thyroid hormones and TSH, tests that

correlated with thyroid status, but not sufficiently specific to diagnose hypothyroidism, were used to diagnose hypothyroidism and to gauge the response to thyroid hormone therapy. The following are previous notable and more recent examples:

- Basal metabolic rate was the “gold standard” for diagnosis. Extremely high and low values correlate well with marked hyperthyroidism and hypothyroidism, respectively, but are affected by many unrelated, diverse conditions, such as fever, pregnancy, cancer, acromegaly, hypogonadism, and starvation (97,98).
- Decrease in sleeping heart rate (61)
- Elevated total cholesterol (62,99) as well as low-density lipoprotein (LDL) (99,100) and the highly atherogenic subfraction Lp (a) (101)
- Delayed Achilles reflex time (60)
- Increased creatine kinase due to an increase in the MM fraction, which can be marked and lead to an increase in the MB fraction. There is a less marked increase in myoglobin (66) and no change in troponin levels even in the presence of an increased MB fraction (102).

#### Screening and aggressive case finding for hypothyroidism

Criteria for population screening include:

- A condition that is prevalent and an important health problem
- Early diagnosis is not usually made
- Diagnosis is simple and accurate
- Treatment is cost effective and safe

Despite this seemingly straightforward guidance, expert panels have disagreed about TSH screening of the general population (Table 8). The ATA recommends screening in all adults beginning at age 35 years and every 5 years thereafter

TABLE 7. THYROTROPIN UPPER NORMAL

Group, study, society	TSH upper normal	Comments
NACB	2.5	When there is no evidence of thyroid disease
NHANES III, disease free	4.5	No self-reported thyroid disease Not on thyroid medications
NHANES III, reference population	4.12	No self-reported thyroid disease Not on thyroid medications Negative anti-thyroid antibodies Not pregnant Not on estrogens, androgens, lithium
Hanford Thyroid Disease Study	4.10	No evidence of thyroid disease Negative anti-thyroid antibodies Not on thyroid medications Normal ultrasound (no nodules or thyroiditis)
Pregnancy, first trimester	2.0–2.5	See sections <i>L-thyroxine treatment of hypothyroidism</i> and <i>Hypothyroidism during pregnancy</i>
Pregnancy, second trimester	3.0	See sections <i>L-thyroxine treatment of hypothyroidism</i> and <i>Hypothyroidism during pregnancy</i>
Pregnancy, third trimester	3.5	See sections <i>L-thyroxine treatment of hypothyroidism</i> and <i>Hypothyroidism during pregnancy</i>

Sources: Stagnaro-Green *et al.*, 2011 (10); Hollowell *et al.*, 2002 (11); Hamilton *et al.*, 2008 (81); Baloch *et al.*, 2003 (85). NACB, National Academy of Clinical Biochemists; NHANES, National Health and Nutrition Examination Survey.

TABLE 8. RECOMMENDATIONS OF SIX ORGANIZATIONS REGARDING SCREENING OF ASYMPTOMATIC ADULTS FOR THYROID DYSFUNCTION

Organization	Screening recommendations
American Thyroid Association	Women and men >35 years of age should be screened every 5 years.
American Association of Clinical Endocrinologists	Older patients, especially women, should be screened.
American Academy of Family Physicians	Patients ≥60 years of age should be screened.
American College of Physicians	Women ≥50 years of age with an incidental finding suggestive of symptomatic thyroid disease should be evaluated.
U.S. Preventive Services Task Force	Insufficient evidence for or against screening
Royal College of Physicians of London	Screening of the healthy adult population unjustified

Sources: Baskin *et al.*, 2002 (2); Ladenson *et al.*, 2000 (103); American Academy of Family Physicians, 2002 (104); Helfand and Redfern, 1998 (105); Vanderpump *et al.*, 1996 (107); Helfand, 2004 (108).

(103). AACE recommends routine TSH measurement in older patients—age not specified—especially women (2). The American Academy of Family Physicians recommends routine screening in asymptomatic patients older than age 60 years (104), and the American College of Physicians recommends case finding in women older than 50 years (105). In contrast, a consensus panel (106), the Royal College of Physicians of London (107), and the U.S. Preventive Services Task Force (108) do not recommend routine screening for thyroid disease in adults. For recommendations in pregnancy, see **Recommendations 20.1.1** and **20.1.2**.

While there is no consensus about population screening for hypothyroidism there is compelling evidence to support case finding for hypothyroidism in:

- Those with autoimmune disease, such as type 1 diabetes (20,21)
- Those with pernicious anemia (109,110)
- Those with a first-degree relative with autoimmune thyroid disease (19)
- Those with a history of neck radiation to the thyroid gland including radioactive iodine therapy for hyperthyroidism and external beam radiotherapy for head and neck malignancies (111–113)
- Those with a prior history of thyroid surgery or dysfunction
- Those with an abnormal thyroid examination
- Those with psychiatric disorders (114)
- Patients taking amiodarone (37) or lithium (32–34)
- Patients with ICD-9 diagnoses as presented in Table 9

#### When to treat hypothyroidism

Although there is general agreement that patients with primary hypothyroidism with TSH levels above 10 mIU/L

TABLE 9. ICD-9-CM CODES TO SUPPORT THYROTROPIN TESTING

Adrenal insufficiency	255.41
Alopecia	704.00
Anemia, unspecified deficiency	281.9
Cardiac dysrhythmia, unspecified	427.9
Changes in skin texture	782.8
Congestive heart failure	428.0
Constipation	564.00
Dementia	294.8BA
Diabetes mellitus, type 1	250.01
Dysmenorrhea	625.3
Hypercholesterolemia	272.0
Hypertension	401.9
Mixed hyperlipidemia	272.2
Malaise and fatigue	780.79
Myopathy, unspecified	359.9
Prolonged QT interval	794.31
Vitiligo	709.01
Weight gain	783.9M

ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification ([www.cdc.gov/nchs/icd/icd9cm.htm](http://www.cdc.gov/nchs/icd/icd9cm.htm)).

should be treated (106,115–117), which patients with TSH levels of 4.5–10 mIU/L will benefit is less certain (118,119). A substantial number of studies have been done on patients with TSH levels between 2.5 and 4.5, indicating beneficial response in atherosclerosis risk factors such as atherogenic lipids (120–123), impaired endothelial function (124,125), and intima media thickness (126). This topic is further discussed in the section *Cardiac benefit from treating subclinical hypothyroidism*. However, there are virtually no clinical outcome data to support treating patients with subclinical hypothyroidism with TSH levels between 2.5 and 4.5 mIU/L. The possible exception to this statement is pregnancy because the rate of pregnancy loss, including spontaneous miscarriage before 20 weeks gestation and stillbirth after 20 weeks, have been reported to be increased in anti-thyroid antibody–negative women with TSH values between 2.5 and 5.0 (127).

#### L-thyroxine treatment of hypothyroidism

Since the generation of biologically active T<sub>3</sub> by the peripheral conversion of T<sub>4</sub> to T<sub>3</sub> was documented in 1970 (128), L-thyroxine monotherapy has become the mainstay of treating hypothyroidism, replacing desiccated thyroid and other forms of L-thyroxine and L-triiodothyronine combination therapy. Although a similar quality of life (129) and circulating T<sub>3</sub> levels (130) have been reported in patients treated with L-thyroxine compared with individuals without thyroid disease, other studies have not shown levels of satisfaction comparable to euthyroid controls (131). A number of studies, following a 1999 report citing the benefit of L-thyroxine and L-triiodothyronine combination therapy (132), have re-addressed the benefits of synthetic L-thyroxine and L-triiodothyronine combination therapy but have largely failed to confirm an advantage of this approach to improve cognitive or mood outcomes in hypothyroid individuals treated with L-thyroxine alone (133,134).

Yet several matters remain uncertain. What should the ratios of L-thyroxine and L-triiodothyronine replacement be (133)? What is the pharmacodynamic equivalence of L-thyroxine and

L-triiodothyronine (135)? It was previously believed to be 1:4, but a recent small study indicated that it was approximately 1:3 (135). Why do some patients prefer combination therapy to L-thyroxine monotherapy (133)? Some insight into the latter question may be gained from a large-scale study of L-thyroxine and L-triiodothyronine combination therapy in which different responses were observed in patients with different genetic subtypes of type 2 deiodinase (136), despite a prior, smaller negative study (137). It is not known if those who responded positively to L-thyroxine and L-triiodothyronine combination therapy will have long-term benefit and whether genotyping patients with hypothyroidism who are clinically and biochemically euthyroid will ultimately reliably identify patients with hypothyroidism who are most likely to benefit from combination therapy.

Treatment of hypothyroidism is best accomplished using synthetic L-thyroxine sodium preparations. Because of the uniqueness of the various tablet formulations and a recently introduced preparation of liquid-containing capsules with the inactive ingredients gelatin, glycerin, and water, and because of uncertainty about the sensitivity of current bioequivalence assessment procedures to assure true interchangeability among the tablets, current recommendations encourage the use of a consistent L-thyroxine preparation for individual patients to minimize variability from refill to refill (138,139).

Some reports have indicated an apparent increased dosage requirement for L-thyroxine in some patients with diminished gastric acid secretion (140,141). This has led to *in vitro* work showing significant differences in dissolution among L-thyroxine preparations (142), profiles of which appear to be dependent on the pH of the solution in which the preparations were dissolved. The liquicap preparation (Tirosint<sup>®</sup>) (143) dissolution profile was the least affected by changes in pH (142). The clinical significance of these findings remains unclear. In more recent, though short-term studies, the use of histamine H<sub>2</sub> receptor blockers and proton pump inhibitors does not appear to influence clinical measures in L-thyroxine tablet-treated patients (144).

Desiccated thyroid has not been systematically studied (see *Dietary supplements and nutraceuticals in the treatment of hypothyroidism*). Absorption studies indicate that the bioavailability of T<sub>3</sub> in desiccated thyroid is comparable to that of orally administered synthetic L-triiodothyronine (145). Therefore, the most commonly used form of desiccated thyroid, known as Armour<sup>®</sup> Thyroid, which is of porcine origin, may be viewed as a L-thyroxine and L-triiodothyronine combination with a ratio of approximately 4:1 by weight (145). The content of thyroid hormone and the ratio of T<sub>4</sub> to T<sub>3</sub> may vary in desiccated thyroid preparations depending on the brand employed and whether it is of porcine or bovine origin.

The daily dosage of L-thyroxine is dependent on age, sex, and body size (146–151). Ideal body weight is best used for clinical dose calculations because lean body mass is the best predictor of daily requirements (152,153). A recent study, however, which did not subclassify patients on the basis of their initial degree of hypothyroidism, found that while the L-thyroxine dose per ideal body weight or degree of overweight differed by sex—with females having a higher dose requirement than men—it did not confirm that age was an independent predictor of dosage (154).

With little residual thyroid function, replacement therapy requires approximately 1.6 µg/kg of L-thyroxine daily (155,156). Patients who are athyreotic (after total thyroid-

ectomy and/or radioiodine therapy) (157) and those with central hypothyroidism may require higher doses (158), while patients with subclinical hypothyroidism (159–162) or after treatment for Graves' disease (163) may require less. Young healthy adults may be started on full replacement dosage, which is also preferred after planned (in preparation for thyroid cancer imaging and therapy) or short-term inadvertent lapses in therapy. Starting with full replacement versus low dosages leads to more rapid normalization of serum TSH but similar time to symptom resolution (164). However, patients with subclinical hypothyroidism do not require full replacement doses (159). Doses of 25–75 µg daily are usually sufficient for achieving euthyroid levels (160), with larger doses usually required for those presenting with higher TSH values (161). One randomized control trial assigned L-thyroxine doses on the basis of the initial serum TSH values as follows: 25 µg for TSH 4.0–8.0 mIU/L, 50 µg for TSH 8–12 mIU/L, and 75 µg for TSH > 12 mIU/L. After 2 months only minimal further adjustments were required to achieve euthyroidism (162).

One recent study demonstrated that L-thyroxine absorption within 30 minutes of breakfast is not as effective as when it is taken 4 hours after the last meal (165). Another study showed that taking it 60 minutes before breakfast on an empty stomach was better than taking it within 2 hours of the last meal of the day, which in turn was better than taking it within 20 minutes of breakfast (166). However, these two studies do not establish which of the two methods, L-thyroxine taken with water 60 minutes before breakfast or at bedtime 4 hours after the last meal on an empty stomach, is superior. Although L-thyroxine is better absorbed when taken 60 minutes before a meal compared to 30 minutes before a meal, compliance may be enhanced by instructing patients to consistently take it with water between 30 and 60 minutes prior to eating breakfast.

L-thyroxine should be stored per product insert at 20°C–25°C, (range, 15°C–30°C) or 68°F–77°F (range, 59°F–86°F) and protected from light and moisture. It should not be taken with substances or medications (see Table 10) that interfere with its absorption or metabolism. Because approximately 70% of an orally administered dose of L-thyroxine is absorbed (167–169), individuals unable to ingest L-thyroxine should initially receive 70% or less of their usual dose intravenously. Crushed L-thyroxine suspended in water should be given to patients receiving enteral feeding through nasogastric and other tubes. For optimal absorption feeding should be interrupted with doses given as long as possible after feeding and at least 1 hour before resuming feeding. Administering intravenous L-thyroxine solution, which is not universally available, should be considered when feeding may not be interrupted.

Dose adjustments are guided by serum TSH determinations 4–8 weeks (156,170) following initiation of therapy, dosage adjustments, or change in the L-thyroxine preparation (139,171). While TSH levels may decline within a month of initiating therapy with doses of L-thyroxine such as 50 or 75 µg, making adjustments with smaller doses may require 8 weeks or longer before TSH levels begin to plateau (170,172). Increment changes of 12.5–25 µg/d are initially made, but even smaller changes may be necessary to achieve goal TSH levels.

In the case of central hypothyroidism, estimates of dosage based on 1.6 µg/kg L-thyroxine daily and assessment of free T<sub>4</sub>, not TSH, should guide therapy. Determinations are best done prior to taking thyroid hormone. The goal of therapy is

TABLE 10. AGENTS AND CONDITIONS HAVING AN IMPACT ON L-THYROXINE THERAPY AND INTERPRETATION OF THYROID TESTS

10.1. Interference with absorption		
Bile acid sequestrants (cholestyramine, colestipol, colesevelam) Sucralfate Cation exchange resins (Kayexelate) Oral bisphosphonates Proton pump inhibitors Raloxifene <sup>a</sup> Multivitamins (containing ferrous sulfate or calcium carbonate) Ferrous sulfate Phosphate binders (sevelamer, aluminum hydroxide)	Calcium salts (carbonate, citrate, acetate) Chromium picolinate Charcoal Orlistat <sup>b</sup> Ciprofloxacin H2 receptor antagonists <sup>a</sup> Malabsorption syndromes <ul style="list-style-type: none"> <li>• Celiac disease</li> <li>• Jejunioileal bypass surgery</li> <li>• Cirrhosis (biliary)</li> <li>• Achlorhydria</li> </ul>	Diet <ul style="list-style-type: none"> <li>• Ingestion with a meal</li> <li>• Grapefruit juice<sup>a</sup></li> <li>• Espresso coffee</li> <li>• High fiber diet</li> <li>• Soybean formula (infants)</li> <li>• Soy</li> </ul>
10.2. Thyroid gland hormone production and secretion		
Direct and indirect effects on the thyroid gland <ul style="list-style-type: none"> <li>• Iodine uptake <ul style="list-style-type: none"> <li>◦ Iodine (including kelp supplements)</li> <li>◦ Amiodarone</li> <li>◦ Ethionamide</li> <li>◦ Iodinated contrast (ipodate,<sup>c</sup> iopanoic acid<sup>c</sup>)</li> <li>◦ Perchlorate<sup>c</sup></li> </ul> </li> <li>• Hormone production <ul style="list-style-type: none"> <li>◦ Iodine (including kelp supplements)</li> <li>◦ Amiodarone</li> <li>◦ Thionamides (carbimazole, methimazole, propylthiouracil)</li> <li>◦ Iodinated contrast (ipodate,<sup>c</sup> iopanoic acid<sup>c</sup>)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>◦ Sulfonylureas</li> <li>◦ Sulfonamides</li> <li>◦ Ethionamide</li> </ul> <ul style="list-style-type: none"> <li>• Secretion <ul style="list-style-type: none"> <li>◦ Lithium</li> <li>◦ Iodine (including kelp supplements)</li> <li>◦ Amiodarone</li> <li>◦ Iodinated contrast (ipodate,<sup>c</sup> iopanoic acid<sup>c</sup>)</li> </ul> </li> <li>• Thyroiditis <ul style="list-style-type: none"> <li>◦ Induces <ul style="list-style-type: none"> <li>- Amiodarone</li> <li>- Tyrosine kinase inhibitors (sunitinib, sorafenib)</li> <li>- Interferon alpha</li> <li>- Interleukins</li> </ul> </li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>- Antiangiogenic (lenalidomide, thalidomide)</li> <li>- Lithium</li> <li>- Alemtuzumab</li> <li>- Denileukin diftitoxin</li> <li>◦ Ameliorates (if autoimmune)</li> <li>- Glucocorticoids</li> <li>• Development of Graves' <ul style="list-style-type: none"> <li>◦ Interferon alpha</li> <li>◦ HAART (highly active antiretroviral therapy)</li> <li>◦ Alemtuzumab</li> </ul> </li> <li>• Amelioration of Graves' <ul style="list-style-type: none"> <li>◦ Glucocorticoids</li> </ul> </li> </ul>
10.3. Direct and indirect effects on the hypothalamic–pituitary–thyroid axis		
TSH secretion <ul style="list-style-type: none"> <li>• Decrease <ul style="list-style-type: none"> <li>◦ Bexarotene</li> <li>◦ Dopamine</li> <li>◦ Dopaminergic agonists (bromocriptine, cabergoline)</li> <li>◦ Glucocorticoids</li> <li>◦ Thyroid hormone analogues</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>◦ Somatostatin analogues (octreotide, lanreotide)</li> <li>◦ Metformin</li> <li>◦ Opiates (e.g., heroin)</li> <li>◦ Interleukin-6</li> </ul> <ul style="list-style-type: none"> <li>• Increase <ul style="list-style-type: none"> <li>◦ Dopamine receptor blockers (metoclopramide)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>◦ Hypoadrenalism</li> <li>◦ Interleukin 2</li> <li>◦ Amphetamine</li> <li>◦ Ritonavir<sup>b</sup></li> <li>◦ St. John's Wort<sup>a</sup></li> </ul> <p>Hypophysitis</p> <ul style="list-style-type: none"> <li>• Ipilimumab</li> </ul>
10.4. Increased clearance		10.5. Peripheral metabolism
Phenobarbital Primidone Phenytoin Carbamazepine Oxcarbazepine <sup>b</sup> Rifampin Growth hormone	Sertraline <sup>b</sup> Tyrosine kinase inhibitors (imatinib, <sup>b</sup> sunitinib) Quetiapine <sup>b</sup> Stavudine <sup>b</sup> Nevirapine <sup>a,b</sup>	Glucocorticoids Amiodarone Propylthiouracil Beta blockers (e.g., propranolol, nadolol) Iodinated contrast (ipodate, <sup>c</sup> iopanoic acid <sup>c</sup> ) Interleukin-6 Clomipramine

<sup>a</sup>Impact uncertain.<sup>b</sup>Mechanism uncertain.<sup>c</sup>Not presently available in the United States.

generally to attain values above the mean for assays being employed, in keeping with observations that mean values for estimates of free  $T_4$  in patients who are treated with L-thyroxine tend to be higher than mean values observed in untreated controls (150,173–175).

Some clinical manifestations of hypothyroidism, such as chronic skin changes, may take up to 3–6 months to resolve after serum TSH has returned to normal (176).

Once an adequate replacement dosage has been determined most, but not all of us, are of the opinion that periodic follow-up evaluations with repeat TSH testing at 6-month and then 12-month intervals are appropriate (172). Some authors think that more frequent testing is advisable to ensure and monitor compliance with therapy.

Dosage adjustments may be necessary as underlying function wanes. In pregnancy thyroid hormone requirements are increased, then revert back to baseline after delivery (177). Dosage adjustments are also necessary, generally when medications influencing absorption, plasma binding, or metabolism are added or discontinued. When such medications are introduced or discontinued thyroid hormone levels should initially be checked within 4–8 weeks of doing so, and tests performed at least every 4–8 weeks until stable euthyroid indices have been documented while on the same dose of L-thyroxine. Decreases in L-thyroxine requirements occur as patients age (151) and following significant weight loss. Moreover, although elderly patients absorb L-thyroxine less efficiently they often require 20–25% less per kilogram daily than younger patients, due to decreased lean body mass (152,153). Regardless of the degree of hypothyroidism, patients older than 50–60 years, without evidence of coronary heart disease (CHD) may be started on doses of 50  $\mu\text{g}$  daily. Among those with known CHD, the usual starting dose is reduced to 12.5–25  $\mu\text{g}/\text{day}$ . Clinical monitoring for the onset of anginal symptoms is essential (178). Anginal symptoms may limit the attainment of euthyroidism. However, optimal medical management of arteriosclerotic cardiovascular disease (ASCVD) should generally allow for sufficient treatment with L-thyroxine to both reduce the serum TSH and maintain the patient angina-free. Emergency coronary artery bypass grafting in patients with unstable angina or left main coronary artery occlusion may be safely performed while the patient is still moderately to severely hypothyroid (179,180) but elective cases should be performed after the patient has become euthyroid.

The exacerbation of adrenal insufficiency was first described in cases of central hypothyroidism over 70 years ago (181). Although it rarely occurs, those with adrenal insufficiency, either primary or central, or at risk for it, should be treated with clinically appropriate doses of hydrocortisone until adrenal insufficiency is ruled out (182,183). In the absence of central hypothyroidism, elevated TSH levels may be seen in conjunction with normal  $T_4$  levels, making it initially indistinguishable from subclinical hypothyroidism. However, when due to adrenal insufficiency elevated TSH levels fall with glucocorticoid therapy alone (54,55).

Patients on high doses of L-thyroxine (>200  $\mu\text{g}/\text{d}$ ) with persistently or frequently elevated TSH levels may be non-compliant or have problems with L-thyroxine absorption (171). The former is much more common (184). Although daily dosing of L-thyroxine is ideal, missed doses should be made up when the omission is recognized, even on the same

or subsequent days. In those with significant compliance problems, weekly dosing with L-thyroxine results in similar clinical safety, outcomes, and acceptable TSH values (185). Absorption is diminished by meals (165,166,168,186) and competing medications (see Table 10).

Steps should be taken to avoid overtreatment with L-thyroxine. This has been reported in 20% of those treated with thyroid hormone (12). The principal adverse consequences of subtle or frank overtreatment are cardiovascular (187–190), skeletal (191–194), and possibly affective disturbances (195–197). The elderly are particularly susceptible to atrial fibrillation, while postmenopausal women, who constitute a substantial portion of those on thyroid hormone, are prone to accelerated bone loss.

### ***Therapeutic endpoints in the treatment of hypothyroidism***

The most reliable therapeutic endpoint for the treatment of primary hypothyroidism is the serum TSH value. Confirmatory total  $T_4$ , free  $T_4$ , and  $T_3$  levels do not have sufficient specificity to serve as therapeutic endpoints by themselves, nor do clinical criteria. Moreover, when serum TSH is within the normal range, free  $T_4$  will also be in the normal range. On the other hand,  $T_3$  levels may be in the lower reference range and occasionally mildly subnormal (150).

The normal range for TSH values, with an upper limit of 4.12 mIU/L is largely based on NHANES III (11) data, but it has not been universally accepted. Some have proposed that the upper normal should be either 2.5 or 3.0 mIU/L (86) for a number of reasons:

- The distribution of TSH values used to establish the normal reference range is skewed to the right by values between 3.1 and 4.12 mIU/L.
- The mean and median values of approximately 1.5 mIU/L are much closer to the lower limit of the reported normal reference range than the upper limit.
- When risk factors for thyroid disease are excluded, the upper reference limit is somewhat lower.

The counter arguments are that while many with TSH values between 2.5–3.0 and 4.12 mIU/L may have early hypothyroidism, many do not. Data to support treating patients in this range are lacking, with the exception of data in pregnancy (see *Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy*). Though patients without thyroid disease have stable mean TSH values, measurements vary up to 50% above (78) and below the mean on a given day. Thus, if the upper normal of TSH were considered to be 2.5 mIU/L, patients with mean values just above the mean NHANES III value of 1.5 mIU/L would frequently be classified as hypothyroid when they are not (78,87). This would lead to more than 10 million additional diagnoses of hypothyroidism in the United States per year—without clear-cut benefit. The controversy has not only contributed to the debate about what TSH values should prompt treatment, but also what the target TSH should be for patients being treated for hypothyroidism. Data concerning clinical benefit are lacking to support targeting to reach low normal or subnormal TSH levels in the treatment of hypothyroidism (198,199). As a result, in patients who are not pregnant, the target range should be within the normal range. If upper and lower normal

values for a third generation TSH assay are not available, the range used should be based on the NHANES III reference population range of 0.45–4.12. Although there are substantial normative data establishing what trimester specific normal ranges are for pregnancy (200–207) (see Table 7, TSH upper range of normal), there are no prospective trials establishing optimal target TSH ranges for patients with hypothyroidism who are pregnant and are being treated with L-thyroxine. The lower range of normal for serum TSH in pregnancy is generally 0.1–0.2 mIU/L lower than the normal range for those who are not pregnant (10).

The appropriate target TSH values treatment for treating patients with differentiated thyroid cancer, goiter, and nodular thyroid disease are beyond the scope of these guidelines.

### **When to consult an endocrinologist**

Although most physicians can diagnose and treat hypothyroidism, consultation with an endocrinologist is recommended in the following situations:

- Children and infants
- Patients in whom it is difficult to render and maintain a euthyroid state
- Pregnancy
- Women planning conception
- Cardiac disease
- Presence of goiter, nodule, or other structural changes in the thyroid gland
- Presence of other endocrine disease such as adrenal and pituitary disorders
- Unusual constellation of thyroid function test results
- Unusual causes of hypothyroidism such as those induced by agents listed in Table 10.

The basis for these recommendations stems from observations that cost-effective diagnostic evaluations and improved outcomes in the medical and surgical evaluation and management of thyroid disorders such as nodular thyroid disease and thyroid cancer are positively correlated with the volume of experience a surgeon has or whether or not the patient was evaluated by an endocrinologist (208–210). In addition, endocrinologists were more knowledgeable about thyroid disease and pregnancy than obstetrician-gynecologists, internists, and family physicians (211). Observational studies comparing care provided by endocrinologists with nonendocrinologists for congenital, pediatric, and central hypothyroidism as well as the uncommon, challenging clinical situations just listed, which are regularly addressed by clinical endocrinologists, are lacking, and controlled studies would be unethical.

### **Concurrent conditions of special significance in hypothyroid patients**

*Hypothyroidism during pregnancy.* Overt untreated hypothyroidism during pregnancy may adversely affect maternal and fetal outcomes. These adverse outcomes include increased incidences of spontaneous miscarriage, preterm delivery, preeclampsia, maternal hypertension, postpartum hemorrhage, low birth weight and stillbirth, and impaired intellectual and psychomotor development of the fetus (212–214). While there is evidence to suggest that subclinical hypothyroidism in early pregnancy may also be associated with impaired intellectual and psychomotor development (215–218), and that this impairment

may be prevented with L-thyroxine treatment (217,218), this is not supported by a recent randomized control trial (219). Finally, women with positive TPOAb may have an increased risk for first trimester miscarriage (220), preterm delivery (221), and for offspring with impaired cognitive development (218,222). This risk may be due to reduced thyroid functional reserve from chronic autoimmune thyroiditis leading to subtle hypothyroidism (223). One European study has shown that treatment with L-thyroxine reduced the risk of miscarriage to that of TPOAb-negative euthyroid controls (224). A recent prospective study done in China showed that intellectual and psychomotor development of offspring born to women with positive TPOAb and normal thyroid function who were treated with L-thyroxine by 8 weeks of gestation had intellectual and psychomotor development comparable to controls (218). Finally, treatment with L-thyroxine before conception has been shown to reduce the miscarriage rate and to increase live birth rate in women with subclinical hypothyroidism undergoing assisted reproduction (225).

A sustained rise in serum total T<sub>4</sub> and a drop in serum TSH characterize the early stage of normal pregnancy. Studies of fetal development and at least one outcome study done in Europe suggest that early central nervous system development requires adequate transplacental T<sub>4</sub> transport (226–231). The offspring of mothers with serum T<sub>4</sub> levels in the lowest 10th percentile of the reference range at the end of the first trimester have been reported to have subnormal intellectual development even if TSH levels are normal (228–231). Based on these findings, desiccated thyroid and L-thyroxine/L-triiodothyronine combinations, which cause lowering of serum T<sub>4</sub> levels, should not be used during pregnancy. Furthermore, patients being treated with these preparations should be switched to L-thyroxine when planning to conceive and at the very latest when found to be pregnant. At this time TSH should also be measured. A more recent study done in Greater Boston, which is iodine sufficient, however, did not demonstrate a relationship between fetal intellectual development and maternal serum T<sub>4</sub> levels (232).

When a woman with hypothyroidism becomes pregnant, the dosage of L-thyroxine should be increased as soon as possible to ensure that serum TSH is <2.5 mIU/L and that serum total T<sub>4</sub> is in the normal reference range for pregnancy. Moreover, when a patient with a positive TPOAb test becomes pregnant, serum TSH should be measured as soon as possible and if it is >2.5 mIU/L, L-thyroxine treatment should be initiated. Serum TSH and total T<sub>4</sub> measurements should be monitored every 4 weeks during the first half of pregnancy (233) and at least once between 26 and 32 weeks gestation to ensure that the requirement for L-thyroxine has not changed. Some of us would continue to monitor thyroid indices after 32 weeks in order to confirm that thyroid indices are in the normal range. L-thyroxine dosages should be adjusted as indicated, aiming for TSH levels that are within the normal range for that phase of pregnancy (177,200–207,234–238). Some advocate doing so more frequently in order to ensure compliance and the efficacy of dose adjustments, as reflected by dropping TSH levels. Total T<sub>4</sub> increases predictably during pregnancy and, as already noted, the reference range is ~1.5 fold that of the nonpregnant range. Serum TSH levels decline in the first trimester when serum human chorionic gonadotropin levels are high and rise after 10–12 weeks gestation. While the upper limit of normal for the first trimester is generally <2.5 mIU/L respective upper normal values for the

second and third trimesters are approximately 3.0 and 3.5 mIU/L.

**Diabetes mellitus.** Approximately 10% of patients with type 1 diabetes mellitus will develop chronic thyroiditis (53) during their lifetime, which may lead to the insidious onset of subclinical hypothyroidism. Patients with diabetes should be examined for the presence and development of a goiter. Sensitive TSH measurements should be obtained at regular intervals in patients with type 1 diabetes, especially if a goiter develops or if evidence is found of other autoimmune disorders. In addition, postpartum thyroiditis will develop in up to 25% of women with type 1 diabetes (239).

**Infertility.** Some patients with infertility and menstrual irregularities have underlying chronic thyroiditis in conjunction with subclinical or overt hypothyroidism. Moreover, TPOAb-positive patients, even when euthyroid, have an excess miscarriage rate (220,224). Typically, these patients seek medical attention because of infertility or a previous miscarriage, rather than hypothyroidism.

A careful, comprehensive history, physical examination, and appropriate laboratory evaluation can identify chronic thyroiditis. It has long been recognized that in some with patients with overt hypothyroidism, thyroid hormone replacement therapy may normalize the menstrual cycle and restore normal fertility (63–65).

**Obesity.** Hypothyroidism and obesity are often linked at least in the consciousness of the lay public. However, appetite in those with marked hypothyroidism is often suppressed offsetting the impact of a decrease in metabolic rate, myxedema may present with weight loss, and overt hypothyroidism does not appear to be more common in the obese population than in the general population (240). Nonetheless this impression dates back to early observations of significant weight loss following the resolution of myxedema, an effect that was principally the result of fluid mobilization (241). This was recently confirmed in a prospective year-long study of newly diagnosed patients with overt hypothyroidism whose mean TSH levels at the onset of the study was 102 (242). Some observational studies correlate TSH levels with body mass index (243–245) while others do not (246). However, obesity may have an impact on the hypothalamic–pituitary–thyroid axis as evidenced by relatively elevated TSH levels in morbidly obese adults (247) and children (248) who have ultrasound findings suggestive of chronic thyroiditis without either elevated anti-thyroid antibody titers or decreased T<sub>4</sub> and T<sub>3</sub> levels. Caution must therefore be exercised when diagnosing subclinical hypothyroidism in the setting of marked obesity (249).

Apart from the mobilization of fluid and the ensuing diuresis in myxedematous states, however, the impact of thyroid hormone therapy on waist–hip ratio (250) and weight loss (242), even in cases of profound hypothyroidism, appears at most to be modest. This is despite the fact that resting energy expenditure increases significantly in individuals who are rendered subclinically hyperthyroid after being subclinically hypothyroid (251). Clearly behavioral and other physiological factors apart from thyroid status have an impact on weight status. Because of the negative impact on nitrogen balance, cardiovascular factors, bone, and affective status, supraphysiological doses of thyroid

hormone as used in the past (252,253) should not be employed as an adjunct to weight loss programs in patients with or without hypothyroidism (254). However, it is advisable to counsel patients about the effect any change in thyroid status may have on weight control. This includes thyroidectomy although recent studies concerning its effect are contradictory (255,256).

**Patients with normal thyroid tests.** Patients with symptoms of hypothyroidism, but normal thyroid hormone levels do not benefit from treatment with L-thyroxine (257). Moreover, treatment confers a substantial risk of subclinical or overt hyperthyroidism, which in one large-scale study was approximately 20% (12).

**Depression.** The diagnosis of subclinical or overt hypothyroidism must be considered in every patient with depression. In fact, a small proportion of all patients with depression have primary hypothyroidism—either overt or subclinical. Those with autoimmune disease are more likely to have depression (258) as are those with postpartum thyroiditis regardless of whether the hypothyroidism is treated or not (259).

All patients receiving lithium therapy require periodic thyroid evaluation because lithium may induce goiter and hypothyroidism (32–34). Occasionally in psychiatric practice, some patients who have depression are treated not only with antidepressants but also with thyroid hormone, even though they have normal thyroid function. No firm evidence has shown that thyroid hormone treatment alone does anything to alleviate depression in such patients.

Substantial evidence supports the use of thyroid hormone to treat the mood disturbances associated with hypothyroidism (114). Interesting animal data link the use of both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) to potential changes in brain thyroid hormone metabolism, which make the combination of L-triiodothyronine with these an appealing therapeutic hypothesis (114). However, the clinical data from randomized controlled trials evaluating the acceleration and augmentation of response with TCA as well as SSRI/L-triiodothyronine combinations are inconsistent (114,260,261) and do not clearly support L-triiodothyronine use in euthyroid depressed subjects.

**Nonthyroidal illness.** The evaluation of thyroid function in chronically or markedly acutely ill patients may be confusing. Medications, such as glucocorticoids (90), amiodarone (37), and dopamine (89) may have an impact on thyroid hormone levels and in the case of amiodarone, a marked effect on thyroid status. In addition, major illness and starvation may be accompanied by a change in thyroid hormone economy, resulting in a low serum T<sub>3</sub> and normal or low serum T<sub>4</sub> and TSH levels (262,263). Since there is evidence that treatment with either L-thyroxine (264) or L-triiodothyronine (265) is of no benefit, patients who are not clearly hypothyroid should not be treated until their acute medical condition has resolved. A 2010 study showed that infants under 5 months of age undergoing cardiac surgery for complex congenital heart disease benefited from intravenous L-triiodothyronine treatment (266), raising the possibility that under certain circumstances treating nonthyroidal illness with thyroid hormone may be beneficial. In addition, patients with NYHA class III or IV heart failure with low serum T<sub>3</sub> levels have been shown to



benefit from intravenous L-triiodothyronine to restore serum T<sub>3</sub> levels to normal (267). Evaluation of the patient by a clinical endocrinologist is appropriate before initiation of thyroid hormone treatment.

### **Dietary supplements and nutraceuticals in the treatment of hypothyroidism**

The majority of dietary supplements (DS) fail to meet a level of scientific substantiation deemed necessary for the treatment of disease (268,269). In the case of hypothyroidism, this is the case for over-the-counter products marketed for “thyroid support” or as a “thyroid supplement” or to promote “thyroid health,” among others. The authors do not recommend the use of these or any unproven therapies (269).

DS are generally thought of as various vitamins, minerals, and other “natural” substances, such as proteins, herbs, and botanicals. The U.S. Food and Drug Administration (FDA) 1994 Dietary Supplement Health and Education Act expanded the definition of DS as follows (270):

*DSHEA 1994 §3(a)*. “(ff) The term ‘dietary supplement’:

- (1) means a product (other than tobacco) that is intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of any [of these ingredients].
- (2) means a product that is intended for ingestion in [pill, capsule, tablet, or liquid form]; is not represented for use as a conventional food or as the sole item of a meal or diet; and is labeled as a dietary supplement.”
- (3) [*paraphrased*] includes products such as an approved new drug, certified antibiotic, or licensed biologic that was marketed as a dietary supplement or food before approval, certification, or license (unless the Secretary of Health and Human Services waives this provision).

Nutraceuticals (N), a term coined to reflect its “nutrition” origin and “pharmaceutical” action, do not have a “regulatory definition.” They are dietary supplements that “contain a concentrated form of a presumed bioactive substance originally derived from a food, but now present in a non-food matrix, and used to enhance health in dosages exceeding those obtainable from normal foods” (268). Guidelines for the use of DS/N in endocrinology have been previously published by AACE (269). Functional foods are those foods containing substances having physiological actions beyond their simple nutritional value.

### **Overlap of symptoms in euthyroid and hypothyroid persons**

The symptoms of hypothyroidism are nonspecific and mimic symptoms that can be associated with variations in lifestyle, in the absence of disease, or those of many other conditions. This is well illustrated in the Colorado thyroid disease prevalence study (12). That study found that four or more symptoms of hypothyroidism were present in approximately 25% of those with overt hypothyroidism, 20% of those

with subclinical hypothyroidism, and in 17% of euthyroid patients. Although the differences were statistically significant since 88% of the population studied was euthyroid, 9% had subclinical hypothyroidism, and only 0.4% were overtly hypothyroid, it is clear that there are many more euthyroid patients with symptoms suggestive of hypothyroidism than those who are subclinically or overtly hypothyroid.

A recent study compared symptoms in euthyroid patients who underwent surgery for benign thyroid disease. Those with Hashimoto’s thyroiditis, the commonest cause of hypothyroidism in iodine sufficient regions, were more likely to complain of chronic fatigue, chronic irritability, chronic nervousness, and lower quality-of life than those without evidence of chronic thyroiditis (271). Nonetheless, the promulgation of claims that substances other than thyroid hormone may reverse these symptoms or influence thyroid status has contributed to the widespread use of alternative therapies for hypothyroidism.

### **Excess iodine intake and hypothyroidism**

Iodine is used as a pharmaceutical in the management of hyperthyroidism and thyroid cancer (as radioiodine). Kelp supplements contain at least 150–250 µg of iodine per capsule compared with the recommended daily intake of iodine of 150 µg for adults who are not pregnant or nursing. In euthyroid patients, especially those with chronic thyroiditis, substantial kelp use may be associated with significant increases in TSH levels (38). No clinical data exist to support the preferential use of stable iodine, kelp, or other iodine-containing functional foods in the management of hypothyroidism in iodine-sufficient regions unless iodine deficiency is strongly suspected and confirmed.

Adverse metabolic effects of iodine supplementation are primarily reported in patients with organification defects (e.g., Hashimoto’s thyroiditis) in which severe hypothyroidism ensues and is referred to as “iodide myxedema” (39,40). Even though pregnant women may be iodine deficient and require supplementation to achieve a total iodine intake of 200–300 µg/d, ingesting kelp or other seaweed-based products is not recommended owing to the variability in iodine content (16,272,273).

### **Desiccated thyroid**

Animal-derived desiccated thyroid (see *L-thyroxine treatment of hypothyroidism*) contains T<sub>4</sub> and T<sub>3</sub>. Since T<sub>3</sub> levels vary substantially throughout the day in those taking desiccated thyroid, T<sub>3</sub> levels cannot be easily monitored. Being viewed by some as a natural source of thyroid hormone has made it attractive to some patients who may not even have biochemically confirmed hypothyroidism and wish to lose weight or increase their sense of well-being (274). There are substantially more data on the use of synthetic L-thyroxine in the management of well-documented hypothyroidism, goiter, and thyroid cancer than for desiccated thyroid hormone. A PubMed computer search of the literature in January 2012 yielded 35 prospective randomized clinical trials (PRCTs) involving synthetic L-thyroxine published in 2007–2011, compared with no PRCTs involving desiccated thyroid extract for all years in the database. Thus, there are no controlled trials supporting the preferred use of desiccated thyroid hormone over synthetic L-thyroxine in the treatment of hypothyroidism or any other thyroid disease.

### 3,5,3'-Triiodothyroacetic acid

Another DS/N used for thyroid health is 3,5,3'-triiodothyroacetic acid (TRIAC; tiratricol), an active metabolite of T<sub>3</sub>, which has been sold over the counter for weight loss. TRIAC appears to have enhanced hepatic and skeletal thyromimetic effects compared with L-thyroxine (275). The FDA scrutinized its use because of its lack of proven benefit as well as thyrotoxic and hypothyroid side effects (276–278). It is difficult to titrate or monitor clinically and biochemically. Its role in the treatment of hypothyroidism in syndromes of generalized resistance to thyroid hormone, particularly when L-thyroxine alone appears to be inadequate, remains uncertain (279,280). There are no data supporting its use in lieu of synthetic L-thyroxine in the treatment of hypothyroidism.

### Thyroid-enhancing preparations

L-tyrosine has been touted as a treatment for hypothyroidism by virtue of its role in thyroid hormone synthesis. There are no preclinical or clinical studies demonstrating that L-tyrosine has thyromimetic properties. B vitamins, garlic, ginger, ginkgo, licorice, magnesium, manganese, meadowsweet, oats, pineapple, potassium, saw palmetto, and valerian are included in various commercially available “thyroid-enhancing preparations.” There are no preclinical or clinical studies demonstrating any thyromimetic properties of any of these DS/N. In a recent study (281), 9 out of 10 thyroid health supplements (marketed as “thyroid support”) studied contained clinically significant amounts of L-thyroxine (>91 µg/d) and/or L-triiodothyronine (>10 µg/day). Physicians should specifically engage patients regarding all forms of DS/N, specifically those marketed as thyroid support, and consider the possibility that any DS/N could be adulterated with L-thyroxine or L-triiodothyronine.

### Thyromimetic preparations

Some DS/N with thyromimetic properties that have been studied but are of unproven clinical benefit include Asian ginseng (282), bladderwrack (283), capsaicin (284), echinacea (285), and forskolin (286).

### Selenium

Selenium is an essential dietary mineral that is part of various selenoenzymes. These compounds are in many antioxidant, oxidation-reduction, and thyroid hormone deiodination pathways. It is not surprising that by virtue of these biochemical effects, selenium has been investigated as a modulator of autoimmune thyroid disease and thyroid hormone economy. In one study, selenium administration was found to reduce the risk for cancer, but in a follow-up study of the study cohort, there was an increased risk of diabetes (287). In a well-designed, European PRCT of 2143 euthyroid women, selenium administration (as 200 µg/d selenomethionine) was associated with a reduction in autoimmune thyroid disease, postpartum thyroiditis, and hypothyroidism (288). Since dietary selenium intake varies worldwide, these results may not be generalizable to all populations. In another PRCT involving 501 patients in the United Kingdom who were over age 60 years, varying doses of selenium (100, 200, or 300 µg/d) for 6 months were not associated with beneficial changes in T<sub>4</sub> to T<sub>3</sub> conversion (289). Most recently, a meta-analysis was performed of blinded PRCTs of patients with

Hashimoto's thyroiditis receiving L-thyroxine therapy (290). The analysis found that selenium supplementation was associated with decreased anti-TPO titers and improved well-being or mood, but there were no significant changes in thyroid gland ultrasonographic morphology or L-thyroxine dosing. Taken together, what do these limited clinical data suggest? Selenium has notable theoretical potential for salutary effects on hypothyroidism and thyroid autoimmunity including Graves' eye disease (291), both as a preventive measure and as a treatment. However, there are simply not enough outcome data to suggest a role at the present time for routine selenium use to prevent or treat hypothyroidism in any population.

## QUESTIONS AND GUIDELINE RECOMMENDATIONS\*

### When should anti-thyroid antibodies be measured?

#### ■ RECOMMENDATION 1

Anti-thyroid peroxidase antibody (TPOAb) measurements should be considered when evaluating patients with subclinical hypothyroidism.

**Grade B, BEL 1**

SEE: *Epidemiology; Primary and secondary etiologies of hypothyroidism*

**Recommendation 1** was downgraded to B because the best evidence is only predictive in nature. If anti-thyroid antibodies are positive, hypothyroidism occurs at a rate of 4.3% per year versus 2.6% per year when anti-thyroid antibodies are negative. Therefore, the presence of positive TPOAb may or may not influence the decision to treat.

#### ■ RECOMMENDATION 2

TPOAb measurement should be considered in order to identify autoimmune thyroiditis when nodular thyroid disease is suspected to be due to autoimmune thyroid disease.

**Grade D, BEL 4**

SEE: *Primary and secondary etiologies of hypothyroidism*

#### ■ RECOMMENDATION 3

TPOAb measurement should be considered when evaluating patients with recurrent miscarriage, with or without infertility.

**Grade A, BEL 2**

SEE: *Concurrent conditions of special significance—Infertility*

**Recommendation 3** was upgraded to A because of favorable risk-benefit potential.

#### ■ RECOMMENDATION 4

Measurement of TSHRABs using a sensitive assay should be considered in hypothyroid pregnant patients with a history of Graves' disease who were treated with radioactive iodine or thyroidectomy prior to pregnancy. This should be initially done either at 20–26 weeks of gestation or during the first trimester and if they are elevated again at 20–26 weeks of gestation.

**Grade A, BEL 2**

SEE: *Primary and secondary etiologies of hypothyroidism*

\*Note: When referring to therapy and therapeutic preparations in the recommendations and elsewhere, L-thyroxine and L-triiodothyronine are generally used instead of their respective hormonal equivalents, T<sub>4</sub> and T<sub>3</sub>.

**Recommendation 4** was upgraded to A because the correlation between a high titer of TSHRab and the development of fetal or neonatal Graves' disease is strong.

**What is the role of clinical scoring systems in the diagnosis of patients with hypothyroidism?**

■ **RECOMMENDATION 5**

Clinical scoring systems should not be used to diagnose hypothyroidism. **Grade A, BEL 1**  
SEE: *Signs and symptoms of hypothyroidism; Other diagnostic tests for hypothyroidism*

**What is the role of diagnostic tests apart from serum thyroid hormone levels and TSH in the evaluation of patients with hypothyroidism?**

■ **RECOMMENDATION 6**

Tests such as clinical assessment of reflex relaxation time, cholesterol, and muscle enzymes should not be used to diagnose hypothyroidism. **Grade B, BEL 2**  
SEE: *Signs and symptoms of hypothyroidism; Other diagnostic tests for hypothyroidism*

**What are the preferred thyroid hormone measurements in addition to TSH in the assessment of patients with hypothyroidism?**

■ **RECOMMENDATION 7**

Apart from pregnancy, assessment of serum free T<sub>4</sub> should be done instead of total T<sub>4</sub> in the evaluation of hypothyroidism. An assessment of serum free T<sub>4</sub> includes a free T<sub>4</sub> index or free T<sub>4</sub> estimate and direct immunoassay of free T<sub>4</sub> without physical separation using anti-T<sub>4</sub> antibody. **Grade A, BEL 1**  
SEE: *Measurement of T<sub>4</sub> and T<sub>3</sub>; Table 6*

■ **RECOMMENDATION 8**

Assessment of serum free T<sub>4</sub>, in addition to TSH, should be considered when monitoring L-thyroxine therapy. **Grade B, BEL 1**

SEE: *Measurement of T<sub>4</sub> and T<sub>3</sub>*

**Recommendation 8** was downgraded to B since it should only be used selectively.

■ **RECOMMENDATION 9**

In pregnancy, the measurement of total T<sub>4</sub> or a free T<sub>4</sub> index, in addition to TSH, should be done to assess thyroid status. Because of the wide variation in the results of different free T<sub>4</sub> assays, direct immunoassay measurement of free T<sub>4</sub> should only be employed when method-specific and trimester-specific reference ranges for serum free T<sub>4</sub> are available. **Grade B, BEL 2**

SEE: *Measurement of T<sub>4</sub> and T<sub>3</sub>*

■ **RECOMMENDATION 10**

Serum total T<sub>3</sub> or assessment of serum free T<sub>3</sub> should not be done to diagnose hypothyroidism. **Grade A, BEL 2**  
SEE: *Measurement of T<sub>4</sub> and T<sub>3</sub>*

**Recommendation 10** was upgraded to A because of many independent lines of evidence and expert opinion.

■ **RECOMMENDATION 11**

TSH measurements in hospitalized patients should be done only if there is an index of suspicion for thyroid dysfunction. **Grade A, BEL 2**

SEE: *Measurement of T<sub>4</sub> and T<sub>3</sub>; Pitfalls encountered when interpreting serum TSH levels; Concurrent conditions of special significance in hypothyroid patients—Nonthyroidal illness*

**Recommendation 11** was upgraded to A because of cost considerations and potential for inappropriate intervention.

■ **RECOMMENDATION 12**

In patients with central hypothyroidism, assessment of free T<sub>4</sub> or free T<sub>4</sub> index, not TSH, should be done to diagnose and guide treatment of hypothyroidism. **Grade A, BEL 1**  
SEE: *Measurement of T<sub>4</sub> and T<sub>3</sub>; L-thyroxine treatment of hypothyroidism*

**When should TSH levels be measured in patients being treated for hypothyroidism?**

■ **RECOMMENDATION 13**

Patients being treated for established hypothyroidism should have serum TSH measurements done at 4–8 weeks after initiating treatment or after a change in dose. Once an adequate replacement dose has been determined, periodic TSH measurements should be done after 6 months and then at 12-month intervals, or more frequently if the clinical situation dictates otherwise. **Grade B, BEL 2**

SEE: *L-thyroxine treatment of hypothyroidism*

**What should be considered the upper limit of the normal range of TSH values?**

■ **RECOMMENDATION 14.1**

The reference range of a given laboratory should determine the upper limit of normal for a third generation TSH assay. The normal TSH reference range changes with age. If an age-based upper limit of normal for a third generation TSH assay is not available in an iodine sufficient area, an upper limit of normal of 4.12 should be considered. **Grade A, BEL 1**

SEE: *Pitfalls encountered when interpreting serum TSH levels; Therapeutic endpoints in the treatment of hypothyroidism; Table 7*

■ **RECOMMENDATION 14.2**

In pregnancy, the upper limit of the normal range should be based on trimester-specific ranges for that laboratory. If trimester-specific reference ranges for TSH are not available in the laboratory, the following upper normal reference ranges are recommended: first trimester, 2.5 mIU/L; second trimester, 3.0 mIU/L; third trimester, 3.5 mIU/L. **Grade B, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7*

**Which patients with TSH levels above a given laboratory's reference range should be considered for treatment with L-thyroxine?**

■ **RECOMMENDATION 15**

Patients whose serum TSH levels exceed 10 mIU/L are at increased risk for heart failure and cardiovascular mortality, and should be considered for treatment with L-thyroxine. **Grade B, BEL 1**

SEE: **Areas for Future Research**; *When to treat hypothyroidism—Cardiac benefit from treating subclinical hypothyroidism*

**Recommendation 15** was downgraded to B because it is not generalizable and meta-analysis does not include prospective interventional studies.

■ **RECOMMENDATION 16**

Treatment based on individual factors for patients with TSH levels between the upper limit of a given laboratory's reference range and 10 mIU/L should be considered particularly if patients have symptoms suggestive of hypothyroidism, positive TPOAb or evidence of atherosclerotic cardiovascular disease, heart failure, or associated risk factors for these diseases. **Grade B, BEL 1**

SEE: *Epidemiology; Primary and secondary etiologies of hypothyroidism; Screening and aggressive case finding for hypothyroidism; When to treat hypothyroidism; Areas for Future Research—Cardiac benefit from treating subclinical hypothyroidism; Table 9*

**Recommendation 16** was downgraded to B because the evidence is not fully generalizable to the stated recommendation and there are no prospective, interventional studies.

**In patients with hypothyroidism being treated with L-thyroxine, what should the target TSH ranges be?**

■ **RECOMMENDATION 17**

In patients with hypothyroidism who are not pregnant, the target range should be the normal range of a third generation TSH assay. If an upper limit of normal for a third generation TSH assay is not available, in iodine-sufficient areas an upper limit of normal of 4.12 mIU/L should be considered and if a lower limit of normal is not available, 0.45 mIU/L should be considered. **Grade B, BEL 2**

SEE: *Pitfalls encountered when interpreting serum TSH levels; When to treat hypothyroidism; Therapeutic endpoints in the treatment of hypothyroidism; Table 7*

**In patients with hypothyroidism being treated with L-thyroxine who are pregnant, what should the target TSH ranges be?**

■ **RECOMMENDATION 18**

In patients with hypothyroidism who are pregnant, the target range for TSH should be based on trimester-specific ranges for that laboratory. If trimester-specific reference ranges are not available in the laboratory, the following upper-normal reference ranges are recommended: first trimester, 2.5 mIU/L; second trimester, 3.0 mIU/L; and third trimester, 3.5 mIU/L. **Grade C, BEL 2**

SEE: *Pitfalls encountered when interpreting serum TSH levels; When to treat hypothyroidism; Therapeutic endpoints in the treatment of hypothyroidism; Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7*

**Recommendation 18** was downgraded to C due to lack of prospective studies establishing benefit.

**Which patients with normal serum TSH levels should be considered for treatment with L-thyroxine?**

■ **RECOMMENDATION 19.1**

Treatment with L-thyroxine *should be considered* in women of childbearing age with serum TSH levels between 2.5 mIU/L and the upper limit of normal for a given laboratory's reference range if they are in the first trimester of pregnancy or planning a pregnancy including assisted reproduction in the immediate future. Treatment with L-thyroxine should be considered in women in the second trimester of pregnancy with serum TSH levels between 3.0 mIU/L and the upper limit of normal for a given laboratory's reference range, and in women in the third trimester of pregnancy with serum TSH levels between 3.5 mIU/L and the upper limit of normal for a given laboratory's reference range. **Grade B, BEL 2**

SEE: *When to treat hypothyroidism; Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7*

■ **RECOMMENDATION 19.2**

Treatment with L-thyroxine *should be considered* in women of childbearing age with normal serum TSH levels when they are pregnant or planning a pregnancy, including assisted reproduction in the immediate future, if they have or have had positive levels of serum TPOAb, particularly when there is a history of miscarriage or past history of hypothyroidism. **Grade B, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7*

■ **RECOMMENDATION 19.3**

Women of childbearing age who are pregnant or planning a pregnancy, including assisted reproduction in the immediate future, *should be treated* with L-thyroxine if they have or have had positive levels of serum TPOAb and their TSH is greater than 2.5 mIU/L. **Grade B, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7*

■ **RECOMMENDATION 19.4**

Women with positive levels of serum TPOAb or with a TSH greater than 2.5 mIU/L who are not being treated with L-thyroxine should be monitored every 4 weeks in the first 20 weeks of pregnancy for the development of hypothyroidism. **Grade B, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7*

**Who, among patients who are pregnant, or planning pregnancy, or with other characteristics, should be screened for hypothyroidism?**

■ **RECOMMENDATION 20.1.1**

Universal screening is not recommended for patients who are pregnant or are planning pregnancy, including assisted reproduction. **Grade B, BEL 1**

SEE: **Areas for Future Research**—*Screening for hypothyroidism in pregnancy*

**Recommendation 20.1.1** was downgraded to B because there are limitations to the evidence and therefore insufficient evidence for lack of benefit.

■ **RECOMMENDATION 20.1.2**

“Aggressive case finding,” rather than universal screening, should be considered for patients who are planning pregnancy. **Grade C, BEL 2**

SEE: **Areas for Future Research**—*Screening for hypothyroidism in pregnancy*

**Recommendation 20.1.2** was downgraded to C because even when a diagnosis of hypothyroidism is made, impact on outcomes has not been demonstrated.

■ **RECOMMENDATION 20.2**

Screening for hypothyroidism should be considered in patients over the age of 60. **Grade B, BEL 1**

SEE: *Epidemiology; Primary and secondary etiologies of hypothyroidism; Screening and aggressive case finding for hypothyroidism; Table 8*

**Recommendation 20.2** was downgraded to B because there is strong evidence that hypothyroidism is common in this group but insufficient evidence of benefit or cost effectiveness.

■ **RECOMMENDATION 21**

“Aggressive case finding” should be considered in those at increased risk for hypothyroidism. **Grade B, BEL 2**

SEE: *Epidemiology; Primary and secondary etiologies of hypothyroidism; Screening and aggressive case finding for hypothyroidism; Table 8*

**How should patients with hypothyroidism be treated and monitored?**

■ **RECOMMENDATION 22.1**

Patients with hypothyroidism should be treated with L-thyroxine monotherapy. **Grade A, BEL 1**

SEE: *L-thyroxine treatment of hypothyroidism*

■ **RECOMMENDATION 22.2**

The evidence does not support using L-thyroxine and L-triiodothyronine combinations to treat hypothyroidism. **Grade B, BEL 1**

SEE: *L-thyroxine treatment of hypothyroidism; Concurrent conditions of special significance in hypothyroid patients; Dietary supplements and nutraceuticals in the treatment of hypothyroidism; Desiccated thyroid; Areas for Future Research*—*L-thyroxine/L-triiodothyronine combination therapy*

**Recommendation 22.2** was downgraded to Grade B because of still-unresolved issues raised by studies that report that some patients prefer and some patient subgroups may benefit from a combination of L-thyroxine and L-triiodothyronine.

■ **RECOMMENDATION 22.3**

L-thyroxine and L-triiodothyronine combinations should not be administered to pregnant women or those planning pregnancy. **Grade B, BEL 3**

SEE: *Concurrent conditions of special significance in hypothyroid patients*—*Hypothyroidism during pregnancy*

**Recommendation 22.3** was upgraded to B because of potential for harm.

■ **RECOMMENDATION 22.4**

There is no evidence to support using desiccated thyroid hormone in preference to L-thyroxine monotherapy in the treatment of hypothyroidism and therefore desiccated thyroid hormone should not be used for the treatment of hypothyroidism. **Grade D, BEL 4**

SEE: *L-thyroxine treatment of hypothyroidism; Dietary supplements and nutraceuticals in the treatment of hypothyroidism; Desiccated thyroid*

**Recommendation 22.4** was a unanimous expert opinion.

■ **RECOMMENDATION 22.5**

3,5,3'-triiodothyroacetic acid (TRIAC; tiratricol) should not be used to treat primary and central hypothyroidism due to suggestions of harm in the literature. **Grade C, BEL 3**

SEE: *Dietary supplements and nutraceuticals in the treatment of hypothyroidism; 3,5,3'-Triiodothyroacetic acid*

■ **RECOMMENDATION 22.6**

Patients resuming L-thyroxine therapy after interruption (less than 6 weeks) and without an intercurrent cardiac event or marked weight loss may resume their previously employed full replacement doses. **Grade D, BEL 4**

SEE: *L-thyroxine treatment of hypothyroidism*

**Recommendation 22.6** was a unanimous expert opinion.

■ **RECOMMENDATION 22.7.1**

When initiating therapy in young healthy adults with overt hypothyroidism, beginning treatment with full replacement doses should be considered. **Grade B, BEL 2**

SEE: *L-thyroxine treatment of hypothyroidism*

■ **RECOMMENDATION 22.7.2**

When initiating therapy in patients older than 50–60 years with overt hypothyroidism, without evidence of coronary heart disease, an L-thyroxine dose of 50  $\mu\text{g}$  daily should be considered. **Grade D, BEL 4**

SEE: *L-thyroxine treatment of hypothyroidism*

**Recommendation 22.7.2** was a unanimous expert opinion.

■ **RECOMMENDATION 22.8**

In patients with subclinical hypothyroidism, initial L-thyroxine dosing is generally lower than what is required in the treatment of overt hypothyroidism. A daily dose of 25–75  $\mu\text{g}$  should be considered, depending on the degree of TSH elevation. Further adjustments should be guided by clinical response and follow-up laboratory determinations including TSH values. **Grade B, BEL 2**

SEE: *L-thyroxine treatment of hypothyroidism*

### ■ RECOMMENDATION 22.9

Treatment with glucocorticoids in patients with combined adrenal insufficiency and hypothyroidism should precede treatment with L-thyroxine.

**Grade B, BEL 2**

SEE: *Disorders associated with hypothyroidism; Pitfalls encountered when trying to interpret serum TSH levels; L-thyroxine treatment of hypothyroidism*

### ■ RECOMMENDATION 23

L-thyroxine should be taken with water consistently 30–60 minutes before breakfast or at bedtime 4 hours after the last meal. It should be stored properly per product insert and not taken with substances or medications that interfere with its absorption.

**Grade B, BEL 2**

SEE: *L-thyroxine treatment of hypothyroidism; Table 10*

### ■ RECOMMENDATION 24

In patients with central hypothyroidism, assessments of serum free T<sub>4</sub> should guide therapy and targeted to exceed the midnormal range value for the assay being used.

**Grade B, BEL 3**

SEE: *Primary and secondary etiologies of hypothyroidism; Measurement of T<sub>4</sub> and T<sub>3</sub>; Pitfalls encountered when interpreting serum TSH levels; L-thyroxine treatment of hypothyroidism*

**Recommendation 24** was upgraded to B because more than 50% of patients with central hypothyroidism adequately treated with L-thyroxine have values in this range.

### ■ RECOMMENDATION 25.1

In patients with hypothyroidism being treated with L-thyroxine who are pregnant, serum TSH should be promptly measured after conception and L-thyroxine dosage adjusted, with a goal TSH of less than 2.5 mIU/L during the first trimester.

**Grade B, BEL 2**

SEE: *Therapeutic endpoints in the treatment of hypothyroidism; Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7*

### ■ RECOMMENDATION 25.2

In patients with hypothyroidism being treated with L-thyroxine who are pregnant, the goal TSH during the second trimester should be less than 3 mIU/L and during the third trimester should be less than 3.5 mIU/L.

**Grade C, BEL 2**

SEE: *Therapeutic endpoints in the treatment of hypothyroidism; Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy; Table 7.*

**Recommendation 25.2** was downgraded to C due to lack of prospective studies establishing benefit.

### ■ RECOMMENDATION 25.3

Maternal serum TSH (and total T<sub>4</sub>) should be monitored every 4 weeks during the first half of pregnancy and at least once between 26 and 32 weeks gestation and L-thyroxine dosages adjusted as indicated.

**Grade B, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Hypothyroidism during pregnancy*

### ■ RECOMMENDATION 26

In patients receiving L-thyroxine treatment for hypothyroidism, serum TSH should be remeasured within 4–8 weeks of initiation of treatment with drugs that decrease the bioavailability or alter the metabolic disposition of the L-thyroxine dose.

**Grade A, BEL 1**

SEE: *L-thyroxine treatment of hypothyroidism; Areas for Future Research—Agents and conditions having an impact on L-thyroxine therapy and interpretation of thyroid tests; Tables 5 and 10.*

### ■ RECOMMENDATION 27

Apart from pregnant patients being treated with L-thyroxine for hypothyroidism, the evidence does not support targeting specific TSH values within the normal reference range.

**Grade B, BEL 2**

SEE: *Therapeutic endpoints in the treatment of hypothyroidism*

### **When should endocrinologists be involved in the care of patients with hypothyroidism?**

### ■ RECOMMENDATION 28

Physicians who are not endocrinologists, but who are familiar with the diagnosis and treatment of hypothyroidism should be able to care for most patients with primary hypothyroidism. However, patients with hypothyroidism who fall into the following categories should be seen in consultation with an endocrinologist. These categories are (i) children and infants, (ii) patients in whom it is difficult to render and maintain a euthyroid state, (iii) pregnancy, (iv) women planning conception, (v) cardiac disease, (vi) presence of goiter, nodule, or other structural changes in the thyroid gland, (vii) presence of other endocrine disease such as adrenal and pituitary disorders, (viii) unusual constellation of thyroid function test results, and (ix) unusual causes of hypothyroidism such as those induced by agents that interfere with absorption of L-thyroxine, impact thyroid gland hormone production or secretion, affect the hypothalamic–pituitary–thyroid axis (directly or indirectly), increase clearance, or peripherally impact metabolism.

**Grade C, BEL 3**

SEE: *When to consult an endocrinologist; Table 10*

### **Which patients should not be treated with thyroid hormone?**

### ■ RECOMMENDATION 29

Thyroid hormones should not be used to treat symptoms suggestive of hypothyroidism without biochemical confirmation of the diagnosis.

**Grade B, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Patients with normal thyroid tests*

### ■ RECOMMENDATION 30

Thyroid hormones should not be used to treat obesity in euthyroid patients.

**Grade A, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Obesity*

**Recommendation 30** was upgraded to Grade A because of potential harm.

### ■ RECOMMENDATION 31

There is insufficient evidence to support using thyroid hormones to treat depression in euthyroid patients.

**Grade B, BEL 2**

SEE: *Concurrent conditions of special significance in hypothyroid patients—Depression*

### **What is the role of iodine supplementation, dietary supplements, and nutraceuticals in the treatment of hypothyroidism?**

#### ■ RECOMMENDATION 32.1

Iodine supplementation, including kelp or other iodine-containing functional foods, should not be used in the management of hypothyroidism in iodine-sufficient areas.

**Grade C, BEL 3**

SEE: *Dietary supplements and nutraceuticals in the treatment of hypothyroidism; Excess iodine intake and hypothyroidism*

#### ■ RECOMMENDATION 32.2

Iodine supplementation in the form of kelp or other seaweed-based products should not be used to treat iodine deficiency in pregnant women.

**Grade D, BEL 4**

SEE: *Dietary supplements and nutraceuticals in the treatment of hypothyroidism; Excess iodine intake and hypothyroidism*

**Recommendation 32.2** was a unanimous expert opinion

#### ■ RECOMMENDATION 33

Selenium should not be used to prevent or treat hypothyroidism.

**Grade B, BEL 2**

SEE: *Dietary supplements and nutraceuticals in the treatment of hypothyroidism; Selenium.*

#### ■ RECOMMENDATION 34

Patients taking dietary supplements and nutraceuticals for hypothyroidism should be advised that commercially available thyroid-enhancing products are not a remedy for hypothyroidism and should be counseled about the potential side effects of various preparations particularly those containing iodine or sympathomimetic amines as well as those marked as “thyroid support” since they could be adulterated with L-thyroxine or L-triiodothyronine.

**Grade D, BEL 4**

SEE: *Dietary supplements and nutraceuticals in the treatment of hypothyroidism; Thyroid enhancing preparations; Thyromimetic preparations*

**Recommendation 34** was a unanimous expert opinion.

## AREAS FOR FUTURE RESEARCH

### **Cardiac benefit from treating subclinical hypothyroidism**

Overt hypothyroidism produces reversible changes in cardiovascular hemodynamics and in many of the modifiable cardiovascular risk factors for ASCVD and heart failure. Some prospective studies also indicate that treatment of subclinical hypothyroidism, including groups with minimally elevated

TSH levels, results in improvement in surrogate markers for ASCVD such as atherogenic lipids (120–123) and carotid intima media thickness (126).

A meta-analysis of 10 longitudinal studies of subclinical hypothyroidism (119), which excluded patients with ASCVD at baseline, showed a relative risk of CHD of 1.2 when all studies were combined. When only higher quality studies were analyzed, the risk dropped to 1.02–1.08 depending on whether the study design allowed for adjudicated outcomes with or without knowledge of thyroid status. However, in studies with mean age younger than 65 years, the risk was 1.51 compared with 1.05 in studies with a mean age of 65 and over. Another meta-analysis, also done in 2008, of 15 studies with over 2500 participants with subclinical hypothyroidism, eight of which were also used in the aforementioned meta-analysis, showed elevated odds ratios for the incidence of ASCVD and cardiovascular all-cause mortality of 1.57 and 1.37 for those under 65 years, but not for those over 65 years (292).

A study from the Cleveland Clinic Preventive Cardiology Clinic of patients at high risk for ASCVD showed that those with TSH levels of 6.1–10 mIU/L as well as greater than 10 mIU/L who were under 65 years and not treated with thyroid hormone had higher all-cause mortality (118). Most recently a U.K. general practitioner database was analyzed to assess the impact of L-thyroxine treatment on fatal and nonfatal cardiac events in over 3000 individuals with subclinical hypothyroidism (TSH between 5.01 and 10 mIU/L) aged between 40 and 70 years and over 1500 individuals older than 70 years who were followed up for a median of ~8 years. In the ~50% of individuals between 40 and 70 years of age who were treated with L-thyroxine (87.4% women) the hazard ratio for ischemic heart disease events was reduced compared to the ~50% of untreated individuals (82.5% women) (0.61, CI 0.49–0.92). This reduction was not evident in those older than 70 years, of whom 84.6% in the treatment group and 75.6% in the untreated group were women (293).

Yet other studies fail to show that an increased risk of cardiac disease in those with subclinical hypothyroidism is age dependent. The Cardiovascular Health Study followed 3000 patients 65 years or older with subclinical hypothyroidism who were initially free of heart failure. Those with TSH levels of 10 mIU/L or greater had an increased risk of heart failure (294). During the 20 years of follow-up in the Wickham Survey, an association was found between ASCVD and ASCVD-related mortality in those with subclinical hypothyroidism whose TSH values were between 6 and 15 mIU/L independent of age. When those treated with L-thyroxine were excluded, ASCVD-related morbidity and mortality were no longer evident (116). Additional large-scale studies in those with serum TSH values of 10 mIU/L or greater including a study of 11 prospective cohorts in the United States, Europe, Australia, Brazil, and Japan demonstrated an increase in ASCVD that was independent of age (115) while a study of six prospective cohorts with over 2000 patients had an increased incidence of heart failure in those up to 80 years of age (117).

The absence of randomized prospective controlled trials leaves us with several unresolved key issues pertaining to subclinical hypothyroidism, including whether or not L-thyroxine treatment will prevent the development of ASCVD

or decrease the frequency of hospital admissions for heart failure and whether age is a critical determinant of risk for cardiac morbidity. A prospective study to assess both of these parameters is currently being planned.

### ***Cognitive benefit from treating subclinical hypothyroidism***

Some reports on mood, cognitive, and other objective brain function studies in subclinical hypothyroidism demonstrate the presence and reversal of deficits after treatment with L-thyroxine (295). However, other studies have not (296,297).

### ***L-thyroxine and L-triiodothyronine combination therapy***

An important question is whether a recent study had sufficient data to warrant revisiting why some patients seem to feel better on L-thyroxine/L-triiodothyronine combinations and whether we can identify them and safely treat them (136) with this combination.

### ***L-triiodothyronine monotherapy***

A potential role for L-triiodothyronine monotherapy in lieu of L-thyroxine monotherapy was recently raised by a small randomized, double-blind crossover intervention study done comparing L-triiodothyronine monotherapy with L-thyroxine monotherapy in patients with hypothyroidism (298). Thrice daily dosing was employed for each. Comparable TSH levels were achieved. Mild weight loss and decreases in total cholesterol, LDL cholesterol, and apolipoprotein levels were seen without differences in cardiovascular function, insulin sensitivity, or quality of life with L-triiodothyronine monotherapy compared with L-thyroxine monotherapy. The small size and short duration of the study as well as thrice daily dosing presently precludes considering L-triiodothyronine monotherapy as an alternative to L-thyroxine monotherapy (298).

### ***Thyroid hormone analogues***

Thyroid hormone's effects are protean, affecting virtually every organ system. Efforts are underway to develop and study analogues that have selective beneficial effects on weight control, lipoproteins, and TSH suppression without inducing hypothyroidism or the most important negative consequences of hyperthyroidism on the heart and skeleton. Compounds studied to date include D-thyroxine (299), tiratricol (275), eprotiromone (KB 2115) (300,301), and diiodothyropropionic acid (302). A recent prospective Phase II clinical trial of the thyroid hormone analogue eprotiromone, designed to be a selective beta II receptor agonist, has been shown to lower both total cholesterol and Lp(a) without any change in thyroid hormone levels or untoward cardiovascular or bone effects (300). However, the development program for eprotiromone has been discontinued due to adverse findings in preclinical studies. Further studies will be needed to confirm the benefit and lack of side effects of these agents.

### ***Screening for hypothyroidism in pregnancy***

It remains unclear if screening for hypothyroidism in pregnancy is beneficial. A consensus statement in 2004 (106) and clinical practice guidelines in 2007 (303) and 2011 (10)

found insufficient data to support a 1999 (304) and restated 2005 recommendation (305) for universal screening for thyroid dysfunction during pregnancy, but rather recommended aggressive case finding.

Arguments for screening include the following:

- Limiting evaluation to women in high-risk groups misses 30% of pregnant women with overt or subclinical hypothyroidism (306).
- A study comparing universal screening to case finding found that there was a statistically significant difference in a composite endpoint of adverse obstetric and neonatal outcomes associated with treatment of thyroid dysfunction in low-risk women who were screened compared to those who were not (307).
- A cost-effectiveness model to evaluate universal screening, which was predicated on the effectiveness of thyroid hormone treatment in lowering the incidence of offspring with intelligence quotient (IQ) < 85, concluded that a random TSH done during the first trimester of pregnancy would ultimately save \$84 per pregnancy (308). However, this has not been confirmed by a recent randomized controlled trial (219).

However, questions remain about the utility of screening those at low risk for developing hypothyroidism (307) and whether screening and intervention earlier on in the first trimester (219) may be cost effective.

The Controlled Antenatal Thyroid Study in the United Kingdom and Italy examined the impact at 3 years of age of L-thyroxine treatment if free T<sub>4</sub> is below the 2.5th percentile or if TSH is above the 97.5th percentile (219). Analyses failed to demonstrate a benefit when screening was performed around the end of the first trimester. Whether earlier intervention, different cognitive testing, or the same testing performed at age greater than 3 years would yield different results is uncertain. "A Randomized Trial of Thyroxine Therapy for Subclinical Hypothyroidism or Hypothyroxinemia Diagnosed During Pregnancy", done under the auspices of the National Institute of Child Health and Human Development, is presently studying the IQ at 5 years of age following a universal screening versus case finding program.

### ***Agents and conditions having an impact on L-thyroxine therapy and interpretation of thyroid tests***

Conditions such as pregnancy and malabsorption, drugs, diagnostic agents, dietary substances, and supplements can have an impact on thyroid hormone economy, which may or may not result in a change in thyroid status. For example, orally administered estrogens increase TBG levels. While this does not alter thyroid status in euthyroid individuals with normal thyroid reserve, it may do so when there is either marginal thyroid reserve or established hypothyroidism. Drugs may have multiple effects on thyroid hormone metabolism. Notable examples include glucocorticoids and amiodarone. In a number of cases, the mechanisms by which agents alter thyroid status are not known. The impact that an agent or condition has on thyroid status may require clinicians to increase monitoring, adjust dosages, or instruct patients to change how and when they take L-thyroxine.



Major determinants of whether or not drugs and other substances will have an impact on thyroid status include the following:

- Dosage
- Duration of action
- Proximity to when thyroid hormone is taken
- Duration of treatment
- Iodine content
- Organified
- Nonorganified
- Size of iodine pool
- Autoimmune thyroid disease
- Nodular thyroid disease
- Thyroid hormone status
- Genetic factors

The principal mechanisms and reasons that conditions, drugs, and other substances have an impact on thyroid status are the following:

- Effects on thyroid hormone metabolism:
  - Absorption
  - Binding
  - Peripheral metabolism
  - Clearance
- Direct and indirect effects on the hypothalamic–pituitary–thyroid axis
  - TSH secretion
  - Hypophysitis
- Direct and indirect effects on the thyroid gland
  - Iodine uptake
  - Hormone production
  - Hormone secretion
- Thyroiditis (amelioration or development)
  - Destructive
  - Autoimmune
- Amelioration or development of Graves' disease

Table 10 lists agents and some conditions that affect thyroid status—particularly if they are commonly used—and are likely to do so or to have a profound impact on it. However, some very commonly used drugs such as sulfonylureas or sulfonamides or foodstuffs such as grapefruit juice that may only have a minor impact have been included. Because of their potential importance, some drugs, such as perchlorate, iopanoic acid, and ipodate, are also listed even though they are not generally available. On the other hand, some drugs that are rarely used have been omitted. Agents may appear more than once if there is more than one known mechanism of action. A comprehensive review of this subject and references for each drug or condition is beyond the scope of these guidelines. The interested reader is encouraged to consult other sources for more information (309–311).

## ACKNOWLEDGMENTS

We thank Dr. Gilbert H. Daniels (Massachusetts General Hospital, Harvard Medical School, Boston, MA), Dr. Daniel S. Duick (Endocrinology Associates P.A., Scottsdale, AZ, and College of Medicine, University of Arizona, Phoenix and Tucson, AZ), and Dr. Sheldon S. Stoffer (Endocrine Consultant, William Beaumont Hospital, Oakland University William Beaumont School of Medicine, Oakland, CA) for their

thoughtful suggestions. Dr. Daniels reports that he has received consultant fees from Genzyme Corporation. Dr. Duick reports that he has received speaker honoraria from Abbott Laboratories and consultant honoraria from Veracyte, Inc. and Asuragen, Inc. Dr. Stoffer reports that he does not have any relevant financial relationships with any commercial interests.

## AUTHOR DISCLOSURE STATEMENT

J.I.M. reports that he has received speaker and program development honoraria from Abbott Nutrition. J.R.G., R.H.C., H.G., J.V.H., I.K., R.P.-P., P.A.S., and K.A.W. report that they do not have any relevant financial relationships with any commercial interests.

## REFERENCES

*Note:* The authors' EL ratings of the references are listed to the right of each reference.

1. Singer PA, Cooper DS, Levy EG, Ladenson PW, EL4  
Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF 1995 Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. *JAMA* **273**:808–812.
2. Baskin HJ, Cobin RH, Duick DS, Gharib H, Guttler RB, EL4  
Kaplan MM, Segal RL 2002 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. *Endocr Pract* **8**:457–469.
3. Garcia M, Baskin HJ, Feld S, Cobin RH, Daniels GH, EL4  
Davidson ET, Dickey RA, Janick JJ, Jellinger PS, Price WF, Rodbard HW 1995 American Association of Clinical Endocrinologists clinical practice guidelines for the evaluation and treatment of hyperthyroidism and hypothyroidism. *Endocr Pract* **1**:54–62.
4. Torres MS, Emerson CH 2011 Myxedema coma. In: EL4  
Irwin RS, Rippe JM (eds) *Irwin & Rippe's Intensive Care Medicine*, 7th edition. Wolters Kluwer Health, Lippencott Williams and Wilkins, Philadelphia, PA, pp 1055–1058.
5. Mechanick JI, Camacho PM, Cobin RH, Garber AJ, EL4  
Garber JR, Gharib H, Petak SM, Rodbard HW, Trencle DL 2010 American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines—2010 update. *Endocr Pract* **16**:270–283.
6. Johnson N 1998 New approaches to the development EL4  
and use of treatment guidelines. *Formulary*. Available at [www.highbeam.com/doc/1P3-32493644.html](http://www.highbeam.com/doc/1P3-32493644.html) (accessed August 19, 2012).
7. Mechanick JI, Kushner RF, Sugeran HJ, Gonzalez- EL4  
Campoy JM, Collazo-Clavell ML, Guven S, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB, Anderson WA, Dixon J 2008 American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and non-surgical support of the bariatric surgery patient. *Endocr Pract* **14**(Suppl 1): 1–83.
8. Bahn Chair RS, Burch HB, Cooper DS, Garber JR, EL4  
Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN 2011 Hyperthyroidism and other causes of thyrotoxi-

- icosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. *Thyroid* **21**:593–646.
9. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN 2011 Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. *Endocr Pract* **17**:456–520. **EL4**
  10. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W 2011 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. *Thyroid* **21**:1081–1125. **EL4**
  11. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* **87**:489–499. **EL1**
  12. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. *Arch Intern Med* **160**:526–534. **EL1**
  13. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P 1985 The aging thyroid. Thyroid deficiency in the Framingham Study. *Arch Intern Med* **145**:1386–1388. **EL1**
  14. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, Young ET 1995 The incidence of thyroid disorders in the community: a twenty-year follow-up of the Wickham Survey. *Clin Endocrinol (Oxf)* **43**:55–68. **EL2**
  15. Vanderpump MP, Tunbridge WM 2002 Epidemiology and prevention of clinical and subclinical hypothyroidism. *Thyroid* **12**:839–847. **EL4**
  16. Andersson M, de Benoist B, Delange F, Zupan J 2007 Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2-years-old: conclusions and recommendations of the Technical Consultation. *Public Health Nutr* **10**:1606–1611. **EL4**
  17. Nerup J 1974 Addison's disease—clinical studies. A report of 108 cases. *Acta Endocrinol (Copenh)* **76**:127–141. **EL3**
  18. Nerup J 1974 Addison's disease—serological studies. *Acta Endocrinol (Copenh)* **76**:142–158. **EL3**
  19. Heward J, Gough SC 1997 Genetic susceptibility to the development of autoimmune disease. *Clin Sci (Lond)* **93**:479–491. **EL3**
  20. Payami H, Joe S, Thomson G 1989 Autoimmune thyroid disease in type I diabetic families. *Genet Epidemiol* **6**:137–141. **EL3**
  21. Torfs CP, King MC, Huey B, Malmgren J, Grumet FC 1986 Genetic interrelationship between insulin-dependent diabetes mellitus, the autoimmune thyroid diseases, and rheumatoid arthritis. *Am J Hum Genet* **38**:170–187. **EL3**
  22. Walker DJ, Griffiths M, Griffiths ID 1986 Occurrence of autoimmune diseases and autoantibodies in multicase rheumatoid arthritis families. *Ann Rheum Dis* **45**:323–326. **EL3**
  23. Grennan DM, Dyer PA, Clague R, Dodds W, Smeaton I, Harris R 1983 Family studies in RA—the importance of HLA-DR4 and of genes for autoimmune thyroid disease. *J Rheumatol* **10**:584–589. **EL3**
  24. Dittmar M, Kahaly GJ 2003 Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. *J Clin Endocrinol Metab* **88**:2983–2992. **EL2**
  25. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA 2000 Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. *Brain* **123**:1102–1111. **EL3**
  26. Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, Tomer Y 2008 Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice. *Proc Natl Acad Sci USA* **105**:14034–14039. **EL3**
  27. Ban Y, Greenberg DA, Davies TF, Jacobson E, Concepcion E, Tomer Y 2008 Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease. *J Clin Endocrinol Metab* **93**:3589–3596. **EL3**
  28. Huber G, Staub JJ, Meier C, Mitrache C, Guglielmetti M, Huber P, Braverman LE 2002 Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. *J Clin Endocrinol Metab* **87**:3221–3226. **EL2**
  29. Kubota S, Fujiwara M, Hagiwara H, Tsujimoto N, Takata K, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A 2010 Multiple thyroid cysts may be a cause of hypothyroidism in patients with relatively high iodine intake. *Thyroid* **20**:205–208. **EL3**
  30. Murdoch JC, Ratcliffe WA, McLarty DG, Rodger JC, Ratcliffe JG 1977 Thyroid function in adults with Down's syndrome. *J Clin Endocrinol Metab* **44**:453–458. **EL3**
  31. Radetti G, Mazzanti L, Paganini C, Bernasconi S, Russo G, Rigon F, Cacciari E 1995 Frequency, clinical and laboratory features of thyroiditis in girls with Turner's syndrome. The Italian Study Group for Turner's Syndrome. *Acta Paediatr* **84**:909–912. **EL3**
  32. Burrow GN, Burke WR, Himmelhoch JM, Spencer RP, Hershman JM 1971 Effect of lithium on thyroid function. *J Clin Endocrinol Metab* **32**:647–652. **EL3**
  33. Bennie EH, Lazarus JH 1972 Lithium-induced thyroid dysfunction. *Lancet* **2**:44–45. **EL4**
  34. Emerson CH, Dysno WL, Utiger RD 1973 Serum thyrotropin and thyroxine concentrations in patients receiving lithium carbonate. *J Clin Endocrinol Metab* **36**:338–346. **EL2**
  35. Fentiman IS, Thomas BS, Balkwill FR, Rubens RD, Hayward JL 1985 Primary hypothyroidism associated with interferon therapy of breast cancer. *Lancet* **1**:1166. **EL4**
  36. Preziati D, La Rosa L, Covini G, Marcelli R, Rescalli S, Persani L, Del Ninno E, Meroni PL, Colombo M, Beck-Peccoz P 1995 Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. *Eur J Endocrinol* **132**:587–593. **EL2**
  37. Martino E, Bartalena L, Bogazzi F, Braverman LE 2001 The effects of amiodarone on the thyroid. *Endocr Rev* **22**:240–254. **EL4**

38. Clark CD, Bassett B, Burge MR 2003 Effects of kelp supplementation on thyroid function in euthyroid subjects. *Endocr Pract* **9**:363–369. **EL3**
39. Braverman LE, Ingbar SH, Vagenakis AG, Adams L, Maloof F 1971 Enhanced susceptibility to iodide myxedema in patients with Hashimoto's disease. *J Clin Endocrinol Metab* **32**:515–521. **EL3**
40. Braverman LE, Vagenakis AG, Wang CA, Maloof F, Ingbar SH 1971 Studies on the pathogenesis of iodide myxedema. *Trans Assoc Am Physicians* **84**:130–138. **EL3**
41. Morshed SA, Latif R, Davies TF 2009 Characterization of thyrotropin receptor antibody-induced signaling cascades. *Endocrinology* **150**:519–529. **EL3**
42. Fu J, Jiang Y, Liang L, Zhu H 2005 Risk factors of primary thyroid dysfunction in early infants born to mothers with autoimmune thyroid disease. *Acta Paediatr* **94**:1043–1048. **EL2**
43. Laurberg P, Nygaard B, Glinoe D, Grussendorf M, Orgiazzi J 1998 Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. *Eur J Endocrinol* **139**:584–586. **EL4**
44. Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ 2011 Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. *J Clin Endocrinol Metab* **96**:3087–3094. **EL2**
45. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK 2006 Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. *Ann Intern Med* **145**:660–664. **EL3**
46. Utiger RD 1965 Radioimmunoassay of human plasma thyrotropin. *J Clin Invest* **44**:1277–1286. **EL1**
47. Beck-Peccoz P, Amr S, Menezes-Ferreira MM, Faglia G, Weintraub BD 1985 Decreased receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of treatment with thyrotropin-releasing hormone. *N Engl J Med* **312**:1085–1090. **EL2**
48. Huang SA, Fish SA, Dorfman DM, Salvatore D, Kozakewich HP, Mandel SJ, Larsen PR 2002 A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. *J Clin Endocrinol Metab* **87**:4457–4461. **EL3**
49. Mouat F, Evans HM, Cutfield WS, Hofman PL, Jefferies C 2008 Massive hepatic hemangioendothelioma and consumptive hypothyroidism. *J Pediatr Endocrinol Metab* **21**:701–703. **EL3**
50. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, Sugawara M 1993 Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. *Thyroid* **3**:93–99. **EL3**
51. Bjorses P, Aaltonen J, Horelli-Kuitunen N, Yaspo ML, Peltonen L 1998 Gene defect behind APECED: a new clue to autoimmunity. *Hum Mol Genet* **7**:1547–1553. **EL4**
52. Meloni A, Furcas M, Cetani F, Marcocci C, Falorni A, Perniola R, Pura M, Boe Wolff AS, Husebye ES, Lilic D, Ryan KR, Gennery AR, Cant AJ, Abinun M, Spickett GP, Arkwright PD, Denning D, Costigan C, Dominguez M, McConnell V, Willcox N, Meager A 2008 Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. *J Clin Endocrinol Metab* **93**:4389–4397. **EL3**
53. Huber A, Menconi F, Corathers S, Jacobson EM, Tomer Y 2008 Joint genetic susceptibility to type 1 diabetes and autoimmune thyroiditis: from epidemiology to mechanisms. *Endocr Rev* **29**:697–725. **EL4**
54. Stryker TD, Molitch ME 1985 Reversible hyperthyrotropinemia, hyperthyroxinemia, and hyperprolactinemia due to adrenal insufficiency. *Am J Med* **79**:271–276. **EL3**
55. Abdullatif HD, Ashraf AP 2006 Reversible subclinical hypothyroidism in the presence of adrenal insufficiency. *Endocr Pract* **12**:572. **EL3**
56. Canaris GJ, Steiner JF, Ridgway EC 1997 Do traditional symptoms of hypothyroidism correlate with biochemical disease? *J Gen Intern Med* **12**:544–550. **EL3**
57. Birket H, Karacalioglu O, Merati AL, Akcam T, Gerek M 2008 Prospective study of the impact of thyroid hormone replacement on objective voice parameters. *Ann Otol Rhinol Laryngol* **117**:523–527. **EL2**
58. Billewicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne E, Young JA 1969 Statistical methods applied to the diagnosis of hypothyroidism. *Q J Med* **38**:255–266. **EL3**
59. Zulewski H, Muller B, Exer P, Miserez AR, Staub JJ 1997 Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. *J Clin Endocrinol Metab* **82**:771–776. **EL3**
60. Lambert EH, Underdahl LO, Beckett S, Mederos LO 1951 A study of the ankle jerk in myxedema. *J Clin Endocrinol Metab* **11**:1186–1205. **EL3**
61. Bell GM, Todd WT, Forfar JC, Martyn C, Wathen CG, Gow S, Riemersma R, Toft AD 1985 End-organ responses to thyroxine therapy in subclinical hypothyroidism. *Clin Endocrinol (Oxf)* **22**:83–89. **EL2**
62. Mason RL, Hunt HM, Hurxthal, LM 1930 Blood cholesterol values in hyperthyroidism and hypothyroidism: their significance. *N Engl J Med* **203**:1273–1278. **EL3**
63. Haines AL, Mussey RD 1935 Certain menstrual disturbances associated with low basal metabolic rates without myxedema. *JAMA* **105**:557–560. **EL3**
64. Foster RC, Thornton, MJ 1939 Thyroid in the treatment of menstrual irregularities. *Endocrinology* **24**:383–388. **EL3**
65. Goldsmith RE, Sturgis SH, Lerman J, Stanbury JB 1952 The menstrual pattern in thyroid disease. *J Clin Endocrinol Metab* **12**:846–855. **EL3**
66. Klein I, Mantell P, Parker M, Levey GS 1980 Resolution of abnormal muscle enzyme studies in hypothyroidism. *Am J Med Sci* **279**:159–162. **EL3**
67. Tajiri J, Shimada T, Naomi S, Umeda T, Sato T 1984 Hepatic dysfunction in primary hypothyroidism. *Endocrinol Jpn* **31**:83–91. **EL3**
68. Surks MI, Sievert R 1995 Drugs and thyroid function. *N Engl J Med* **333**:1688–1694. **EL4**
69. Oppenheimer JH, Squef R, Surks MI, Hauer H 1963 Binding of thyroxine by serum proteins evaluated by equilibrium dialysis and electrophoretic techniques. Alterations in nonthyroidal illness. *J Clin Invest* **42**:1769–1782. **EL1**

70. Mendel CM 1989 The free hormone hypothesis: a physiologically based mathematical model. *Endocr Rev* **10**:232–274. **EL4**
71. Stockigt JR 2001 Free thyroid hormone measurement. A critical appraisal. *Endocrinol Metab Clin North Am* **30**:265–289. **EL4**
72. Ain KB, Pucino F, Shiver TM, Banks SM 1993 Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. *Thyroid* **3**:81–85. **EL3**
73. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, Goodwin TM 2009 Free T4 immunoassays are flawed during pregnancy. *Am J Obstet Gynecol* **200**:260 e261–266. **EL2**
74. Mandel SJ, Spencer CA, Hollowell JG 2005 Are detection and treatment of thyroid insufficiency in pregnancy feasible? *Thyroid* **15**:44–53. **EL4**
75. Lum SM, Nicoloff JT, Spencer CA, Kaptein EM 1984 Peripheral tissue mechanism for maintenance of serum triiodothyronine values in a thyroxine-deficient state in man. *J Clin Invest* **73**:570–575. **EL3**
76. Kaplan MM, Larsen PR, Crantz FR, Dzau VJ, Rossing TH, Haddow JE 1982 Prevalence of abnormal thyroid function test results in patients with acute medical illnesses. *Am J Med* **72**:9–16. **EL2**
77. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G 2003 Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. *J Clin Endocrinol Metab* **88**:3202–3211. **EL3**
78. Caron PJ, Nieman LK, Rose SR, Nisula BC 1986 Deficient nocturnal surge of thyrotropin in central hypothyroidism. *J Clin Endocrinol Metab* **62**:960–964. **EL3**
79. Karmisholt J, Andersen S, Laurberg P 2008 Variation in thyroid function tests in patients with stable untreated subclinical hypothyroidism. *Thyroid* **18**:303–308. **EL2**
80. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, Gray D, Nicoloff JT 1990 Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. *J Clin Endocrinol Metab* **70**:453–460. **EL3**
81. Hamilton TE, Davis S, Onstad L, Kopecky KJ 2008 Thyrotropin levels in a population with no clinical, autoantibody, or ultrasonographic evidence of thyroid disease: implications for the diagnosis of subclinical hypothyroidism. *J Clin Endocrinol Metab* **93**:1224–1230. **EL1**
82. Volzke H, Alte D, Kohlmann T, Ludemann J, Nauck M, John U, Meng W 2005 Reference intervals of serum thyroid function tests in a previously iodine-deficient area. *Thyroid* **15**:279–285. **EL2**
83. Volzke H, Schmidt CO, John U, Wallaschofski H, Dorr M, Nauck M 2010 Reference levels for serum thyroid function tests of diagnostic and prognostic significance. *Horm Metab Res* **42**:809–814. **EL2**
84. Boucai L, Hollowell JG, Surks MI 2011 An approach for development of age-, gender-, and ethnicity-specific thyrotropin reference limits. *Thyroid* **21**:5–11. **EL1**
85. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR 2003 Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid* **13**:3–126. **EL4**
86. Wartofsky L, Dickey RA 2005 The evidence for a narrower thyrotropin reference range is compelling. *J Clin Endocrinol Metab* **90**:5483–5488. **EL4**
87. Surks MI, Goswami G, Daniels GH 2005 The thyrotropin reference range should remain unchanged. *J Clin Endocrinol Metab* **90**:5489–5496. **EL4**
88. Surks MI, Hollowell JG 2007 Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. *J Clin Endocrinol Metab* **92**:4575–4582. **EL1**
89. Kaptein EM, Spencer CA, Kamiel MB, Nicoloff JT 1980 Prolonged dopamine administration and thyroid hormone economy in normal and critically ill subjects. *J Clin Endocrinol Metab* **51**:387–393. **EL2**
90. Sowers JR, Carlson HE, Brautbar N, Hershman JM 1977 Effect of dexamethasone on prolactin and TSH responses to TRH and metoclopramide in man. *J Clin Endocrinol Metab* **44**:237–241. **EL2**
91. Wong ET, Bradley SG, Schultz AL 1981 Elevations of thyroid-stimulating hormone during acute non-thyroidal illness. *Arch Intern Med* **141**:873–875. **EL3**
92. Lightman SL, Fox P, Dunne MJ 1986 The effect of SMS 201–995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. *Scand J Gastroenterol Suppl* **119**:84–95. **EL2**
93. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M 1999 Central hypothyroidism associated with retinoid X receptor-selective ligands. *N Engl J Med* **340**:1075–1079. **EL3**
94. Lawson EA, Klibanski A 2008 Endocrine abnormalities in anorexia nervosa. *Nat Clin Pract Endocrinol Metab* **4**:407–414. **EL3**
95. Gershengorn MC, Weintraub BD 1975 Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of “inappropriate secretion of TSH”. *J Clin Invest* **56**:633–642. **EL3**
96. Halsall DJ, English E, Chatterjee VK 2009 Interference from heterophilic antibodies in TSH assays. *Ann Clin Biochem* **46**:345–346. **EL4**
97. Boothby WM, Sandiford I 1929 Normal values of basal or standard metabolism. A modification of the Dubois standards. *Am J Physiol* **90**:290–291. **EL3**
98. Werner SC 1955 Basal metabolism. In: Werner SC (ed) *The Thyroid: A Fundamental and Clinical Text*. First edition. Harper & Brothers, New York, pp 125–136. **EL4**
99. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA 1977 The spectrum of thyroid disease in a community: the Wickham survey. *Clin Endocrinol (Oxf)* **7**:481–493. **EL1**
100. de Bruin TW, van Barlingen H, van Linde-Sibenius Trip M, van Vuurst de Vries AR, Akveld MJ, Erkelens DW 1993 Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects. *J Clin Endocrinol Metab* **76**:121–126. **EL3**
101. Danese MD, Ladenson PW, Meinert CL, Powe NR 2000 Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid

- failure: a quantitative review of the literature. *J Clin Endocrinol Metab* **85**:2993–3001.
102. Ness-Abramof R, Nabriski DA, Shapiro MS, Tripto-Shkolnik L, Katz B, Weiss E, Shenkman L 2009 Cardiac troponin T is not increased in patients with hypothyroidism. *Intern Med J* **39**:117–120. **EL3**
  103. Ladenson PW, Singer PA, Ain KB, Bagchi N, Bigos ST, Levy EG, Smith SA, Daniels GH, Cohen HD 2000 American Thyroid Association guidelines for detection of thyroid dysfunction. *Arch Intern Med* **160**:1573–1575. **EL4**
  104. American Academy of Family Physicians 2002 Summary of policy recommendations for periodic health examinations. American Academy of Family Physicians: Leawood, KS. **EL4**
  105. Helfand M, Redfern CC 1998 Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. *Ann Intern Med* **129**:144–158. **EL4**
  106. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA* **291**:228–238. **EL4**
  107. Vanderpump MP, Ahlquist JA, Franklyn JA, Clayton RN 1996 Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology. *BMJ* **313**:539–544. **EL4**
  108. Helfand M 2004 Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med* **140**:128–141. **EL4**
  109. Tudhope GR, Wilson GM 1962 Deficiency of vitamin B12 in hypothyroidism. *Lancet* **1**:703–706. **EL3**
  110. Carmel R, Spencer CA 1982 Clinical and subclinical thyroid disorders associated with pernicious anemia. Observations on abnormal thyroid-stimulating hormone levels and on a possible association of blood group O with hyperthyroidism. *Arch Intern Med* **142**:1465–1469. **EL3**
  111. Glatstein E, McHardy-Young S, Brast N, Eltringham JR, Kriss JP 1971 Alterations in serum thyrotropin (TSH) and thyroid function following radiotherapy in patients with malignant lymphoma. *J Clin Endocrinol Metab* **32**:833–841. **EL3**
  112. Constine LS, Donaldson SS, McDougall IR, Cox RS, Link MP, Kaplan HS 1984 Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. *Cancer* **53**:878–883. **EL3**
  113. Liening DA, Duncan NO, Blakeslee DB, Smith DB 1990 Hypothyroidism following radiotherapy for head and neck cancer. *Otolaryngol Head Neck Surg* **103**:10–13. **EL3**
  114. Hennessey JV, Jackson IMD. 1996 The interface between thyroid hormones and psychiatry. *Endocrinologist* **6**:214–223. **EL4**
  115. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO, Iervasi G, Imaizumi M, Collet TH, Bremner A, Maisonneuve P, Sgarbi JA, Khaw KT, Vanderpump MP, Newman AB, Cornuz J, Franklyn JA, Westendorp RG, Vittinghoff E, Gusekloo J 2010 Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *JAMA* **304**:1365–1374. **EL3**
  116. Razvi S, Weaver JU, Vanderpump MP, Pearce SH 2010 The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. *J Clin Endocrinol Metab* **95**:1734–1740. **EL3**
  117. Gencer B, Collet TH, Virgini V, Bauer DC, Gusekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N 2012 Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from six prospective cohorts. *Circulation* **126**:1040–1049. **EL1**
  118. McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ 2011 Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. *Thyroid* **21**:837–843. **EL3**
  119. Ochs N, Auer R, Bauer DC, Nanchen D, Gusekloo J, Cornuz J, Rodondi N 2008 Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. *Ann Intern Med* **148**:832–845. **EL1**
  120. Dessein PH, Joffe BI, Stanwix AE 2004 Subclinical hypothyroidism is associated with insulin resistance in rheumatoid arthritis. *Thyroid* **14**:443–446. **EL3**
  121. Serter R, Demirbas B, Korukluoglu B, Culha C, Cakal E, Aral Y 2004 The effect of L-thyroxine replacement therapy on lipid based cardiovascular risk in subclinical hypothyroidism. *J Endocrinol Invest* **27**:897–903. **EL2**
  122. Iqbal A, Jorde R, Figenschau Y 2006 Serum lipid levels in relation to serum thyroid-stimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. *J Intern Med* **260**:53–61. **EL1**
  123. Caraccio N, Ferrannini E, Monzani F 2002 Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. *J Clin Endocrinol Metab* **87**:1533–1538. **EL2**
  124. Taddei S, Caraccio N, Viridis A, Dardano A, Versari D, Ghiadoni L, Salvetti A, Ferrannini E, Monzani F 2003 Impaired endothelium-dependent vasodilation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. *J Clin Endocrinol Metab* **88**:3731–3737. **EL3**
  125. Dardano A, Caraccio N, Monzani F 2006 Evaluation of endothelial function in subclinical thyroid dysfunction. *Thyroid* **16**:200–201. **EL4**
  126. Dardano A, Monzani F 2007 Thyroid function and carotid artery intima-media thickness. *Circ J* **71**:993. **EL4**
  127. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A 2010 Increased pregnancy loss rate in thyroid antibody negative women with TSH levels between 2.5 and 5.0 in the first trimester of pregnancy. *J Clin Endocrinol Metab* **95**:E44–48. **EL2**
  128. Braverman LE, Ingbar SH, Sterling K 1970 Conversion of thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects. *J Clin Invest* **49**:855–864. **EL1**

129. Petersen K, Bengtsson C, Lapidus L, Lindstedt G, Nystrom E 1990 Morbidity, mortality, and quality of life for patients treated with levothyroxine. *Arch Intern Med* **150**:2077–2081. **EL2**
130. Jonklaas J, Davidson B, Bhagat S, Soldin SJ 2008 Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. *JAMA* **299**:769–777. **EL2**
131. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM 2002 Psychological well-being in patients on ‘adequate’ doses of L-thyroxine: results of a large, controlled community-based questionnaire study. *Clin Endocrinol (Oxf)* **57**:577–585. **EL2**
132. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ Jr 1999 Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. *N Engl J Med* **340**:424–429. **EL2**
133. Escobar-Morreale HF, Botella-Carretero JJ, Escobar del Rey F, Morreale de Escobar G 2005 REVIEW: Treatment of hypothyroidism with combinations of levothyroxine plus liothyronine. *J Clin Endocrinol Metab* **90**:4946–4954. **EL4**
134. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L 2006 Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab* **91**:2592–2599. **EL1**
135. Celi FS, Zemskova M, Linderman JD, Babar NI, Skarulis MC, Csako G, Wesley R, Costello R, Penzak SR, Pucino F 2010 The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients. *Clin Endocrinol (Oxf)* **72**:709–715. **EL2**
136. Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley AT, Frayling TM, Dayan CM 2009 Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. *J Clin Endocrinol Metab* **94**:1623–1629. **EL3**
137. Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Fliers E 2005 Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3'-triiodothyronine therapy. *J Clin Endocrinol Metab* **90**:6296–6299. **EL3**
138. Hennessey JV, Malabanan AO, Haugen BR, Levy EG 2010 Adverse event reporting in patients treated with levothyroxine: results of the pharmacovigilance task force survey of the American Thyroid Association, American Association of Clinical Endocrinologists, and the Endocrine Society. *Endocr Pract* **16**:357–370. **EL3**
139. AACE, TES and ATA Joint position statement on the use and interchangeability of thyroxine products. Available at <https://www.aace.com/files/position-statements/aace-tes-ata-thyroxineproducts.pdf> (accessed August 19, 2012). **EL4**
140. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, Annibale B 2006 Thyroxine in goiter, *Helicobacter pylori* infection, and chronic gastritis. *N Engl J Med* **354**:1787–1795. **EL3**
141. Sachmechi I, Reich DM, Aninyei M, Wibowo F, Gupta G, Kim PJ 2007 Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. *Endocr Pract* **13**:345–349. **EL2**
142. Pabla D, Akhlaghi F, Zia H 2009 A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. *Eur J Pharm Biopharm* **72**:105–110. **EL4**
143. U.S. Food and Drug Administration 2008 Tirosint™ (Levothyroxine Sodium) Capsules. Available at [www.accessdata.fda.gov/drugsatfda\\_docs/nda/2006/021924s000TOC.cfm](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021924s000TOC.cfm) (accessed August 19, 2012). **EL4**
144. Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN 2008 The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. *Thyroid* **18**:493–498. **EL2**
145. LeBoff MS, Kaplan MM, Silva JE, Larsen PR 1982 Bioavailability of thyroid hormones from oral replacement preparations. *Metabolism* **31**:900–905. **EL2**
146. Rosenbaum RL, Barzel US 1982 Levothyroxine replacement dose for primary hypothyroidism decreases with age. *Ann Intern Med* **96**:53–55. **EL3**
147. Roti E, Minelli R, Gardini E, Braverman LE 1993 The use and misuse of thyroid hormone. *Endocr Rev* **14**:401–423. **EL4**
148. Mandel SJ, Brent GA, Larsen PR 1993 Levothyroxine therapy in patients with thyroid disease. *Ann Intern Med* **119**:492–502. **EL4**
149. Toft AD 1994 Thyroxine therapy. *N Engl J Med* **331**:174–180. **EL4**
150. Woeber KA 2002 Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations. *J Endocrinol Invest* **25**:106–109. **EL2**
151. Sawin CT, Herman T, Molitch ME, London MH, Kramer SM 1983 Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. *Am J Med* **75**:206–209. **EL3**
152. Cunningham JJ, Barzel US 1984 Lean body mass is a predictor of the daily requirement for thyroid hormone in older men and women. *J Am Geriatr Soc* **32**:204–207. **EL3**
153. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, Giannetti M, Taddei D, Centoni R, Scartabelli G, Rago T, Mammoli C, Elisei R, Vitti P 2005 Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. *J Clin Endocrinol Metab* **90**:124–127. **EL3**
154. Devdhar M, Drooger R, Pehlivanova M, Singh G, Jonklaas J 2011 Levothyroxine replacement doses are affected by gender and weight, but not age. *Thyroid* **21**:821–827. **EL2**
155. Hennessey JV, Evalul JE, Tseng YC, Burman KD, Wartofsky L 1986 L-thyroxine dosage: a reevaluation of therapy with contemporary preparations. *Ann Intern Med* **105**:11–15. **EL3**
156. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH 1987 Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. *N Engl J Med* **316**:764–770. **EL2**
157. Kabadi UM, Jackson T 1995 Serum thyrotropin in primary hypothyroidism. A possible predictor of **EL3**

- optimal daily levothyroxine dose in primary hypothyroidism. *Arch Intern Med* **155**:1046–1048.
158. Gordon MB, Gordon MS 1999 Variations in adequate levothyroxine replacement therapy in patients with different causes of hypothyroidism. *Endocr Pract* **5**:233–238. **EL3**
  159. Rosenbaum RL, Barzel US 1981 Clinical hypothyroidism in the elderly—a preventable disorder? *J Am Geriatr Soc* **29**:221–223. **EL3**
  160. Miller MJ, Pan C, Barzel US 1990 The prevalence of subclinical hypothyroidism in adults with low-normal blood thyroxine levels. *NY State J Med* **90**:541–544. **EL3**
  161. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B 2001 TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). *J Clin Endocrinol Metab* **86**:4860–4866. **EL2**
  162. Teixeira PF, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Melo BA, Buescu A, Costa AJ, Vaisman M 2008 Treatment of subclinical hypothyroidism reduces atherogenic lipid levels in a placebo-controlled double-blind clinical trial. *Horm Metab Res* **40**:50–55. **EL2**
  163. Bearcroft CP, Toms GC, Williams SJ, Noonan K, Monson JP 1991 Thyroxine replacement in post-radioiodine hypothyroidism. *Clin Endocrinol (Oxf)* **34**:115–118. **EL3**
  164. Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP, Berghout A 2005 The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. *Arch Intern Med* **165**:1714–1720. **EL2**
  165. Bolk N, Visser TJ, Nijman J, Jongste IJ, Tijssen JG, Berghout A 2010 Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. *Arch Intern Med* **170**:1996–2003. **EL2**
  166. Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J 2009 Timing of levothyroxine administration affects serum thyrotropin concentration. *J Clin Endocrinol Metab* **94**:3905–3912. **EL2**
  167. Hays MT 1988 Thyroid hormone and the gut. *Endocr Res* **14**:203–224. **EL4**
  168. Hays MT, Nielsen KR 1994 Human thyroxine absorption: age effects and methodological analyses. *Thyroid* **4**:55–64. **EL2**
  169. Wenzel KW, Kirschsieper HE 1977 Aspects of the absorption of oral L-thyroxine in normal man. *Metabolism* **26**:1–8. **EL2**
  170. Maeda M, Kuzuya N, Masuyama Y, Imai Y, Ikeda H 1976 Changes in serum triiodothyronine, thyroxine, and thyrotropin during treatment with thyroxine in severe primary hypothyroidism. *J Clin Endocrinol Metab* **43**:10–17. **EL2**
  171. Wiersinga WM 2010 Hypothyroidism and myxedema coma. In: Jameson JL, DeGroot LJ (eds) *Endocrinology: Adult and Pediatric*, 6th edition. Saunders Elsevier, Philadelphia, PA, pp 1607–1622. **EL4**
  172. Brajkovich IE, Mashiter K, Joplin GF, Cassar J 1983 Serum T4, T3, and TSH levels in primary hypothyroidism during replacement therapy with thyroxine. *Metabolism* **32**:745–747. **EL2**
  173. Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, Peper M, Lubrich B, Hug MJ, Nauck M, Olschewski M, Beuschlein F, Reincke M 2007 Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. *J Clin Endocrinol Metab* **92**:4115–4122. **EL2**
  174. Iverson JF, Mariash CN 2008 Optimal free thyroxine levels for thyroid hormone replacement in hypothyroidism. *Endocr Pract* **14**:550–555. **EL3**
  175. Koulouri O, Auldin MA, Agarwal R, Kieffer V, Robertson C, Falconer Smith J, Levy MJ, Howlett TA 2011 Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. *Clin Endocrinol (Oxf)* **74**:744–749. **EL3**
  176. Gabilove JL, Ludwig AW 1957 The histogenesis of myxedema. *J Clin Endocrinol Metab* **17**:925–932. **EL2**
  177. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR 2004 Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. *N Engl J Med* **351**:241–249. **EL2**
  178. Keating FR Jr, Parkin TW, Selby JB, Dickinson LS 1961 Treatment of heart disease associated with myxedema. *Prog Cardiovasc Dis* **3**:364–381. **EL3**
  179. Ladenson PW, Levin AA, Ridgway EC, Daniels GH 1984 Complications of surgery in hypothyroid patients. *Am J Med* **77**:261–266. **EL3**
  180. Drucker DJ, Burrow GN 1985 Cardiovascular surgery in the hypothyroid patient. *Arch Intern Med* **145**:1585–1587. **EL3**
  181. Means JH, Hertz S, Lerman J. 1940 The pituitary type of myxedema or Simmond's disease masquerading as myxedema. *Trans Assoc Am Physicians* **55**:32. **EL3**
  182. Peterson RE 1958 The influence of the thyroid on adrenal cortical function. *J Clin Invest* **37**:736–743. **EL2**
  183. Peterson RE, Wyngaarden JB 1956 The miscible pool and turnover rate of hydrocortisone in man. *J Clin Invest* **35**:552–561. **EL2**
  184. Ain KB, Refetoff S, Fein HG, Weintraub BD 1991 Pseudomalabsorption of levothyroxine. *JAMA* **266**:2118–2120. **EL3**
  185. Grebe SK, Cooke RR, Ford HC, Fagerstrom JN, Cordwell DP, Lever NA, Purdie GL, Feek CM 1997 Treatment of hypothyroidism with once weekly thyroxine. *J Clin Endocrinol Metab* **82**:870–875. **EL2**
  186. Lamson MJ, Pamplin CL, Roller RL, Klein I 2004 Quantitation of a substantial reduction in levothyroxine (T4) reduction by food. *Thyroid* **14**:876 (abstract). **EL3**
  187. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* **331**:1249–1252. **EL2**
  188. Shapiro LE, Sievert R, Ong L, Ocampo EL, Chance RA, Lee M, Nanna M, Ferrick K, Surks MI 1997 Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. *J Clin Endocrinol Metab* **82**:2592–2595. **EL3**

189. Biondi B, Fazio S, Cuocolo A, Sabatini D, Nicolai E, Lombardi G, Salvatore M, Sacca L 1996 Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* **81**:4224–4228. **EL3**
190. Abdulrahman RM, Delgado V, Hoftijzer HC, Ng AC, Ewe SH, Marsan NA, Holman ER, Hovens GC, Corssmit EP, Romijn JA, Bax JJ, Smit JW 2011 Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma. *Thyroid* **21**:471–476. **EL2**
191. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B 1990 Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. *Ann Intern Med* **113**:265–269. **EL3**
192. Faber J, Galloe AM 1994 Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. *Eur J Endocrinol* **130**:350–356. **EL2**
193. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY 1996 Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. *J Clin Endocrinol Metab* **81**:4278–4289. **EL2**
194. Bauer DC, Ettinger B, Nevitt MC, Stone KL 2001 Risk for fracture in women with low serum levels of thyroid-stimulating hormone. *Ann Intern Med* **134**:561–568. **EL2**
195. Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, Bellastella A, Lombardi G, Sacca L 1994 Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. *J Clin Endocrinol Metab* **78**:1028–1033. **EL3**
196. Botella-Carretero JI, Galan JM, Caballero C, Sancho J, Escobar-Morreale HF 2003 Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. *Endocr Relat Cancer* **10**:601–610. **EL3**
197. Samuels MH 2008 Cognitive function in untreated hypothyroidism and hyperthyroidism. *Curr Opin Endocrinol Diabetes Obes* **15**:429–433. **EL4**
198. Walsh JP, Ward LC, Burke V, Bhagat CI, Shiels L, Henley D, Gillett MJ, Gilbert R, Tanner M, Stuckey BG 2006 Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. *J Clin Endocrinol Metab* **91**:2624–2630. **EL2**
199. Boeving A, Paz-Filho G, Radominski RB, Graf H, Amaral de Carvalho G 2011 Low-normal or high-normal thyrotropin target levels during treatment of hypothyroidism: a prospective, comparative study. *Thyroid* **21**:355–360. **EL2**
200. Stricker R, Echenard M, Eberhart R, Chevailler MC, Perez V, Quinn FA 2007 Evaluation of maternal thyroid function during pregnancy: the importance of using gestational age-specific reference intervals. *Eur J Endocrinol* **157**:509–514. **EL2**
201. Gilbert RM, Hadlow NC, Walsh JP, Fletcher SJ, Brown SJ, Stuckey BG, Lim EM 2008 Assessment of thyroid function during pregnancy: first-trimester (weeks 9–13) reference intervals derived from Western Australian women. *Med J Aust* **189**:250–253. **EL2**
202. Bocos-Terraz JP, Izquierdo-Alvarez S, Bancalero-Flores JL, Alvarez-Lahuerta R, Aznar-Sauca A, Real-Lopez E, Ibanez-Marco R, Bocanegra-Garcia V, Rivera-Sanchez G 2009 Thyroid hormones according to gestational age in pregnant Spanish women. *BMC Res Notes* **2**:237. **EL3**
203. Haddow JE, Knight GJ, Palomaki GE, McClain MR, Pulkkinen AJ 2004 The reference range and within-person variability of thyroid stimulating hormone during the first and second trimesters of pregnancy. *J Med Screen* **11**:170–174. **EL2**
204. Mannisto T, Surcel HM, Ruokonen A, Vaarasmaki M, Pouta A, Bloigu A, Jarvelin MR, Hartikainen AL, Suvanto E 2011 Early pregnancy reference intervals of thyroid hormone concentrations in a thyroid antibody-negative pregnant population. *Thyroid* **21**:291–298. **EL2**
205. Marwaha RK, Chopra S, Gopalakrishnan S, Sharma B, Kanwar RS, Sastry A, Singh S 2008 Establishment of reference range for thyroid hormones in normal pregnant Indian women. *BJOG* **115**:602–606. **EL2**
206. Panesar NS, Li CY, Rogers MS 2001 Reference intervals for thyroid hormones in pregnant Chinese women. *Ann Clin Biochem* **38**:329–332. **EL2**
207. Soldin OP, Soldin D, Sastoque M 2007 Gestation-specific thyroxine and thyroid stimulating hormone levels in the United States and worldwide. *Ther Drug Monit* **29**:553–559. **EL1**
208. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. *Ann Surg* **228**:320–330. **EL3**
209. Ortiz R, Hupart KH, DeFesi CR, Surks MI 1998 Effect of early referral to an endocrinologist on efficiency and cost of evaluation and development of treatment plan in patients with thyroid nodules. *J Clin Endocrinol Metab* **83**:3803–3807. **EL3**
210. Kumar H, Daykin J, Holder R, Watkinson JC, Sheppard MC, Franklyn JA 2001 An audit of management of differentiated thyroid cancer in specialist and non-specialist clinic settings. *Clin Endocrinol (Oxf)* **54**:719–723. **EL3**
211. Rinaldi MD, Stagnaro-Green AS 2007 Thyroid disease and pregnancy: degrees of knowledge. *Thyroid* **17**:747–753. **EL3**
212. Davis LE, Leveno KJ, Cunningham FG 1988 Hypothyroidism complicating pregnancy. *Obstet Gynecol* **72**:108–112. **EL3**
213. Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH 1993 Perinatal outcome in hypothyroid pregnancies. *Obstet Gynecol* **81**:349–353. **EL3**
214. Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, Cunningham FG 2005 Subclinical hypothyroidism and pregnancy outcomes. *Obstet Gynecol* **105**:239–245. **EL2**
215. Teng W, Shan Z 2011 Pregnancy and thyroid diseases in China. *Thyroid* **21**:1053–1055. **EL4**
216. Li Y, Shan Z, Teng W, Yu X, Fan C, Teng X, Guo R, Wang H, Li J, Chen Y, Wang W, Chawinga M, Zhang L, Yang L, Zhao Y, Hua T 2010 Abnormalities of maternal thyroid function during pregnancy affect neuropsychological development of their children at 25–30 months. *Clin Endocrinol (Oxf)* **72**:825–829. **EL2**



217. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ 1999 Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. *N Engl J Med* **341**:549–555. **EL2**
218. Yu X, Shan Z, Teng W, Xue H, Li YB, Wang W, Li J, Chen Y, Li J, Fan C, Wang H, Zhang H, Guo R 2010 A prospective study on impact of subclinical hypothyroidism during pregnancy receiving levothyroxine treatment or not on neuropsychological development of the offspring. ITC 2010-1037. *14th International Thyroid Conference*, Paris, France, September 11–16. **EL2**
219. Lazarus JH, Bestwick JP, Channon S, Paradise R, Maina A, Rees R, Chiusano E, John R, Guaraldo V, George LM, Perona M, Dall'Amico D, Parkes AB, Joomun M, Wald NJ 2012 Antenatal thyroid screening and childhood cognitive function. *N Engl J Med* **366**:493–501. **EL1**
220. Stagnaro-Green A, Roman SH, Cobin RH, el-Harazy E, Alvarez-Marfany M, Davies TF 1990 Detection of at-risk pregnancy by means of highly sensitive assays for thyroid autoantibodies. *JAMA* **264**:1422–1425. **EL2**
221. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A 2011 Thyroid antibody positivity in the first trimester of pregnancy is associated with negative pregnancy outcomes. *J Clin Endocrinol Metab* **96**:E920–924. **EL3**
222. Pop VJ, de Vries E, van Baar AL, Waelkens JJ, de Rooy HA, Horsten M, Donkers MM, Komproe IH, van Son MM, Vader HL 1995 Maternal thyroid peroxidase antibodies during pregnancy: a marker of impaired child development? *J Clin Endocrinol Metab* **80**:3561–3566. **EL3**
223. Glinioer D, Riahi M, Grun JP, Kinthaert J 1994 Risk of subclinical hypothyroidism in pregnant women with asymptomatic autoimmune thyroid disorders. *J Clin Endocrinol Metab* **79**:197–204. **EL2**
224. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H 2006 Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. *J Clin Endocrinol Metab* **91**:2587–2591. **EL2**
225. Kim CH, Ahn JW, Kang SP, Kim SH, Chae HD, Kang BM 2011 Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/intracytoplasmic sperm injection. *Fertil Steril* **95**:1650–1654. **EL2**
226. Morreale de Escobar G, Obregon MJ, Escobar del Rey F 2000 Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? *J Clin Endocrinol Metab* **85**:3975–3987. **EL4**
227. Morreale de Escobar G 2001 The role of thyroid hormone in fetal neurodevelopment. *J Pediatr Endocrinol Metab* **14 Suppl 6**:1453–1462. **EL4**
228. Pop VJ, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, Vulmsa T, Wiersinga WM, Drexhage HA, Vader HL 1999 Low maternal free thyroxine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin Endocrinol (Oxf)* **50**:149–155. **EL3**
229. Pop VJ, Brouwers EP, Vader HL, Vulmsa T, van Baar AL, de Vijlder JJ 2003 Maternal hypothyroxinaemia during early pregnancy and subsequent child development: a 3-year follow-up study. *Clin Endocrinol (Oxf)* **59**:282–288. **EL3**
230. Kooistra L, Crawford S, van Baar AL, Brouwers EP, Pop VJ 2006 Neonatal effects of maternal hypothyroxinemia during early pregnancy. *Pediatrics* **117**:161–167. **EL3**
231. Henrichs J, Bongers-Schokking JJ, Schenk JJ, Ghasabian A, Schmidt HG, Visser TJ, Hooijkaas H, de Muinck Keizer-Schrama SM, Hofman A, Jaddoe VV, Visser W, Steegers EA, Verhulst FC, de Rijke YB, Tiemeier H 2010 Maternal thyroid function during early pregnancy and cognitive functioning in early childhood: the generation R study. *J Clin Endocrinol Metab* **95**:4227–4234. **EL3**
232. Oken E, Braverman LE, Platek D, Mitchell ML, Lee SL, Pearce EN 2009 Neonatal thyroxine, maternal thyroid function, and child cognition. *J Clin Endocrinol Metab* **94**:497–503. **EL2**
233. Yassa L, Marqusee E, Fawcett R, Alexander EK 2010 Thyroid hormone early adjustment in pregnancy (the THERAPY) trial. *J Clin Endocrinol Metab* **95**:3234–3241. **EL2**
234. Mandel SJ, Larsen PR, Seely EW, Brent GA 1990 Increased need for thyroxine during pregnancy in women with primary hypothyroidism. *N Engl J Med* **323**:91–96. **EL3**
235. Tamaki H, Amino N, Takeoka K, Mitsuda N, Miyai K, Tanizawa O 1990 Thyroxine requirement during pregnancy for replacement therapy of hypothyroidism. *Obstet Gynecol* **76**:230–233. **EL3**
236. Kaplan MM 1992 Monitoring thyroxine treatment during pregnancy. *Thyroid* **2**:147–152. **EL3**
237. Kaplan MM, Meier DA 1998 Thyroid diseases in pregnancy. In: Gleicher N (ed) *Principles and Practice of Medical Therapy in Pregnancy*, 3rd edition. Appleton & Lange, Stamford, CT, pp 432–448. **EL4**
238. Verga U, Bergamaschi S, Cortelazzi D, Ronzoni S, Marconi AM, Beck-Peccoz P 2009 Adjustment of L-T4 substitutive therapy in pregnant women with subclinical, overt or post-ablative hypothyroidism. *Clin Endocrinol (Oxf)* **70**:798–802. **EL3**
239. Alvarez-Marfany M, Roman SH, Drexler AJ, Robertson C, Stagnaro-Green A 1994 Long-term prospective study of postpartum thyroid dysfunction in women with insulin dependent diabetes mellitus. *J Clin Endocrinol Metab* **79**:10–16. **EL3**
240. Glass AR, Kushner J. 1996 Obesity, nutrition, and the thyroid. *Endocrinologist* **6**:392–404. **EL4**
241. Plummer WA 1940 Body weight in spontaneous myxedema. *Transactions of the American Association for the Study of Goiter*, pp 88–98. **EL2**
242. Karmisholt J, Andersen S, Laurberg P 2011 Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. *J Clin Endocrinol Metab* **96**:E99–103. **EL2**
243. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, Jorgensen T 2005 Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. *J Clin Endocrinol Metab* **90**:4019–4024. **EL3**

244. Nyrnes A, Jorde R, Sundsfjord J 2006 Serum TSH is positively associated with BMI. *Int J Obes (Lond)* **30**:100–105. **EL3**
245. Fox CS, Pencina MJ, D'Agostino RB, Murabito JM, Seely EW, Pearce EN, Vasan RS 2008 Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. *Arch Intern Med* **168**:587–592. **EL2**
246. Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, Franklyn JA 2006 Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. *Clin Endocrinol (Oxf)* **64**:125–128. **EL3**
247. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE 2006 Thyroid function in humans with morbid obesity. *Thyroid* **16**:73–78. **EL2**
248. Radetti G, Kleon W, Buzi F, Crivellaro C, Pappalardo L, di Iorgi N, Maghnie M 2008 Thyroid function and structure are affected in childhood obesity. *J Clin Endocrinol Metab* **93**:4749–4754. **EL2**
249. Rotondi M, Magri F, Chiovato L 2011 Thyroid and obesity: not a one-way interaction. *J Clin Endocrinol Metab* **96**:344–346. **EL4**
250. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU 2007 The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. *J Clin Endocrinol Metab* **92**:1715–1723. **EL2**
251. al-Adsani H, Hoffer LJ, Silva JE 1997 Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. *J Clin Endocrinol Metab* **82**:1118–1125. **EL2**
252. Gwinup G, Poucher R 1967 A controlled study of thyroid analogs in the therapy of obesity. *Am J Med Sci* **254**:416–420. **EL2**
253. Rivlin RS 1975 Therapy of obesity with hormones. *N Engl J Med* **292**:26–29. **EL4**
254. Kaptein EM, Beale E, Chan LS 2009 Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. *J Clin Endocrinol Metab* **94**:3663–3675. **EL2**
255. Jonklaas J, Nsouli-Maktabi H 2011 Weight changes in euthyroid patients undergoing thyroidectomy. *Thyroid* **21**:1343–1351. **EL3**
256. Weinreb JT, Yang Y, Braunstein GD 2011 Do patients gain weight after thyroidectomy for thyroid cancer? *Thyroid* **21**:1339–1342. **EL3**
257. Pollock MA, Sturrock A, Marshall K, Davidson KM, Kelly CJ, McMahan AD, McLaren EH 2001 Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. *BMJ* **323**:891–895. **EL2**
258. Pop VJ, Maartens LH, Leusink G, van Son MJ, Knottnerus AA, Ward AM, Metcalfe R, Weetman AP 1998 Are autoimmune thyroid dysfunction and depression related? *J Clin Endocrinol Metab* **83**:3194–3197. **EL3**
259. Harris B, Oretti R, Lazarus J, Parkes A, John R, Richards C, Newcombe R, Hall R 2002 Randomised trial of thyroxine to prevent postnatal depression in thyroid-antibody-positive women. *Br J Psychiatry* **180**:327–330. **EL1**
260. Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B 2007 Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. *Arch Gen Psychiatry* **64**:679–688. **EL2**
261. Posternak M, Novak S, Stern R, Hennessey J, Joffe R, Prange A Jr, Zimmerman M 2008 A pilot effectiveness study: placebo-controlled trial of adjunctive L-triiodothyronine (T3) used to accelerate and potentiate the antidepressant response. *Int J Neuropsychopharmacol* **11**:15–25. **EL2**
262. Slag MF, Morley JE, Elson MK, Crowson TW, Nuttall FQ, Shafer RB 1981 Hypothyroxinemia in critically ill patients as a predictor of high mortality. *JAMA* **245**:43–45. **EL3**
263. Kaptein EM, Weiner JM, Robinson WJ, Wheeler WS, Nicoloff JT 1982 Relationship of altered thyroid hormone indices to survival in nonthyroidal illnesses. *Clin Endocrinol (Oxf)* **16**:565–574. **EL3**
264. Brent GA, Hershman JM 1986 Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. *J Clin Endocrinol Metab* **63**:1–8. **EL2**
265. Becker RA, Vaughan GM, Ziegler MG, Seraile LG, Goldfarb IW, Mansour EH, McManus WF, Pruitt BA Jr, Mason AD Jr 1982 Hypermetabolic low triiodothyronine syndrome of burn injury. *Crit Care Med* **10**:870–875. **EL2**
266. Portman MA, Slee A, Olson AK, Cohen G, Karl T, Tong E, Hastings L, Patel H, Reinhartz O, Mott AR, Mainwaring R, Linam J, Danzi S 2010 Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis. *Circulation* **122**:S224–233. **EL2**
267. Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D, L'Abbate A, Mariotti R, Iervasi G 2008 Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. *J Clin Endocrinol Metab* **93**:1351–1358. **EL2**
268. Zeisel SH 1999 Regulation of "nutraceuticals". *Science* **285**:1853–1855. **EL4**
269. Mechanick JI, Brett EM, Chausmer AB, Dickey RA, Wallach S 2003 American Association of Clinical Endocrinologists medical guidelines for the clinical use of dietary supplements and nutraceuticals. *Endocr Pract* **9**:417–470. **EL4**
270. Scally MC, Hodge A 2000 Health supplement regulations and consumer protection rights. *South Med J* **93**:1230–1232. **EL4**
271. Ott J, Promberger R, Kober F, Neuhold N, Tea M, Huber JC, Hermann M 2011 Hashimoto's thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. *Thyroid* **21**:161–167. **EL2**
272. Zimmermann M, Delange F 2004 Iodine supplementation of pregnant women in Europe: a review and recommendations. *Eur J Clin Nutr* **58**:979–984. **EL4**

273. Fumarola A, Calvanese A, D'Armiento M 2009 Iodine intake in pregnancy. *Int J Gynaecol Obstet* **104**:147–148. **EL4**
274. Clarke N, Kabadi UM 2004 Optimizing treatment of hypothyroidism. *Treat Endocrinol* **3**:217–221. **EL4**
275. Sherman SI, Ringel MD, Smith MJ, Kopelen HA, Zoghbi WA, Ladenson PW 1997 Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. *J Clin Endocrinol Metab* **82**:2153–2158. **EL3**
276. Chan WB, Chow CC, Cockram CS 2004 A patient with low free T4 and low thyroid-stimulating hormone without hypopituitarism. *Int J Clin Pract* **58**:983–984. **EL3**
277. Scally MC, Hodge A 2003 A report of hypothyroidism induced by an over-the-counter fat loss supplement (Tiratricol). *Int J Sport Nutr Exerc Metab* **13**:112–116. **EL3**
278. Bauer BA, Elkin PL, Erickson D, Klee GG, Brennan MD 2002 Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol. *Mayo Clin Proc* **77**:587–590. **EL3**
279. Messier N, Laflamme L, Hamann G, Langlois MF 2001 In vitro effect of Triac on resistance to thyroid hormone receptor mutants: potential basis for therapy. *Mol Cell Endocrinol* **174**:59–69. **EL3**
280. Ueda S, Takamatsu J, Fukata S, Tanaka K, Shimizu N, Sakata S, Yamaji T, Kuma K, Ohsawa N 1996 Differences in response of thyrotropin to 3,5,3'-triiodothyronine and 3,5,3'-triiodothyroacetic acid in patients with resistance to thyroid hormone. *Thyroid* **6**:563–570. **EL3**
281. Kang GY, Parks J, Fileta BB, Chang AS, Abdel-Rahm M, Burch HB, Bernet V 2011 Thyroxine and triiodothyronine content in commercially available thyroid health supplements. American Thyroid Association 81st Annual Meeting, Indian Wells, CA, October 26–30. **EL3**
282. Dai X, Zhou Y, Yu X 1999 [Effect of ginseng injection in treating congestive heart failure and its influence on thyroid hormones]. *Zhongguo Zhong Xi Yi Jie He Za Zhi* **19**:209–211. **EL3**
283. Skibola CF 2004 The effect of *Fucus vesiculosus*, an edible brown seaweed, upon menstrual cycle length and hormonal status in three pre-menopausal women: a case report. *BMC Complement Altern Med* **4**:10. **EL4**
284. Masuda Y, Haramizu S, Oki K, Ohnuki K, Watanabe T, Yazawa S, Kawada T, Hashizume S, Fushiki T 2003 Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog. *J Appl Physiol* **95**:2408–2415. **EL4**
285. Barnes J, Anderson LA, Gibbons S, Phillipson JD 2005 Echinacea species (*Echinacea angustifolia* (DC.) Hell., *Echinacea pallida* (Nutt.) Nutt., *Echinacea purpurea* (L.) Moench): a review of their chemistry, pharmacology and clinical properties. *J Pharm Pharmacol* **57**:929–954. **EL4**
286. Venkateswaran A, Marsee DK, Green SH, Jhiang SM 2004 Forskolin, 8-Br-3',5'-cyclic adenosine 5'-monophosphate, and catalytic protein kinase A expression in the nucleus increase radioiodide uptake and sodium/iodide symporter protein levels in RET/PTC1-expressing cells. *J Clin Endocrinol Metab* **89**:6168–6172. **EL3**
287. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, Cappuccio FP, Ceriello A, Reid ME 2007 Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. *Ann Intern Med* **147**:217–223. **EL1**
288. Negro R, Greco G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H 2007 The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. *J Clin Endocrinol Metab* **92**:1263–1268. **EL1**
289. Rayman MP, Thompson AJ, Bekaert B, Catterick J, Galassini R, Hall E, Warren-Perry M, Beckett GJ 2008 Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. *Am J Clin Nutr* **87**:370–378. **EL1**
290. Toulis KA, Anastasilakis AD, Tzellos TG, Goulis DG, Kouvelas D 2010 Selenium supplementation in the treatment of Hashimoto's thyroiditis: a systematic review and a meta-analysis. *Thyroid* **20**:1163–1173. **EL2**
291. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W 2011 Selenium and the course of mild Graves' orbitopathy. *N Engl J Med* **364**:1920–1931. **EL2**
292. Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH 2008 The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. *J Clin Endocrinol Metab* **93**:2998–3007. **EL2**
293. Razvi S, Weaver JU, Butler TJ, Pearce SH 2012 Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. *Arch Intern Med*. [Epub ahead of print]. **EL1**
294. Rodondi N, Bauer DC, Cappola AR, Cornuz J, Robbins J, Fried LP, Ladenson PW, Vittinghoff E, Gottdiener JS, Newman AB 2008 Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. *J Am Coll Cardiol* **52**:1152–1159. **EL2**
295. Correia N, Mullally S, Cooke G, Tun TK, Phelan N, Feeney J, Fitzgibbon M, Boran G, O'Mara S, Gibney J 2009 Evidence for a specific defect in hippocampal memory in overt and subclinical hypothyroidism. *J Clin Endocrinol Metab* **94**:3789–3797. **EL2**
296. Jorde R, Waterloo K, Storhaug H, Nyrnes A, Sundsfjord J, Jenssen TG 2006 Neuropsychological function and symptoms in subjects with subclinical hypothyroidism and the effect of thyroxine treatment. *J Clin Endocrinol Metab* **91**:145–153. **EL2**
297. Parle J, Roberts L, Wilson S, Pattison H, Roalfe A, Haque MS, Heath C, Sheppard M, Franklyn J, Hobbs FD 2010 A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. *J Clin Endocrinol Metab* **95**:3623–3632. **EL2**
298. Celi FS, Zemskova M, Linderman JD, Smith S, Drinkard B, Sachdev V, Skarulis MC, Kozlosky M, Csako G, Costello R, Pucino F 2011 Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. *J Clin Endocrinol Metab* **96**:3466–3474. **EL2**

299. Strisower EH, Strisower B 1964 The separate hypolipoproteinemic effects of dextrothyroxine and ethyl chlorophenoxyisobutyrate. *J Clin Endocrinol Metab* **24**:139–144. **EL3**
300. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B 2010 Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. *N Engl J Med* **362**:906–916. **EL1**
301. Berkenstam A, Kristensen J, Mellstrom K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjoberg F, Angelin B, Baxter JD 2008 The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. *Proc Natl Acad Sci USA* **105**:663–667. **EL2**
302. Ladenson PW, McCarren M, Morkin E, Edson RG, Shih MC, Warren SR, Barnhill JG, Churby L, Thai H, O'Brien T, Anand I, Warner A, Hattler B, Dunlap M, Erikson J, Goldman S 2010 Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. *J Clin Endocrinol Metab* **95**:1349–1354. **EL1**
303. Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoe D, Mandel SJ, Stagnaro-Green A 2007 Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* **92**:S1–47. **EL4**
304. Gharib HC, Cobin RH, Dickey RA 1999 Subclinical hypothyroidism during pregnancy: position statement from the American Association of Clinical Endocrinologists. *Endocr Pract* **5**:367–368. **EL4**
305. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT 2005 Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. *J Clin Endocrinol Metab* **90**:581–585; discussion 586–587. **EL2**
306. Vaidya B, Anthony S, Bilous M, Shields B, Drury J, Hutchison S, Bilous R 2007 Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk case finding? *J Clin Endocrinol Metab* **92**:203–207. **EL2**
307. Negro R, Schwartz A, Gismondi R, Tinelli A, Mangieri T, Stagnaro-Green A 2010 Universal screening versus case finding for detection and treatment of thyroid hormonal dysfunction during pregnancy. *J Clin Endocrinol Metab* **95**:1699–1707. **EL1**
308. Thung SF, Funai EF, Grobman WA 2009 The cost-effectiveness of universal screening in pregnancy for subclinical hypothyroidism. *Am J Obstet Gynecol* **200**:267 e261–267. **EL4**
309. Weiss RE, Refetoff S 2010 Thyroid function testing. In: Jameson JL, DeGroot LJ (eds) *Endocrinology: Adult and Pediatric*, 6th edition. Saunders Elsevier, Philadelphia, PA, pp 1444–1492. **EL4**
310. Barbesino G 2010 Drugs affecting thyroid function. *Thyroid* **20**:763–770. **EL4**
311. Hamnvik OP, Larsen PR, Marqusee E 2011 Thyroid dysfunction from antineoplastic agents. *J Natl Cancer Inst* **103**:1572–1578. **EL4**

Address correspondence to:

*Jeffrey R. Garber, M.D.*

*Endocrinology Division*

*Harvard Vanguard Medical Associates*

*133 Brookline Avenue*

*Boston, MA 02215*

*E-mail: jgarber@bidmc.harvard.edu*